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Abstract 
The aim of this research thesis was to explore the structure-activity relationship 
(SAR) of ferrocenyl-peptide bioconjugates and to explore methods by which these 
compounds exert their anti-proliferative on cancer cells. Furthermore, the 
applicability across different cell types including cancer cells which have acquired 
resistance to chemotherapeutics and non-cancerous cells was investigated. Finally, 
we attempted to overcome the insolubility of the ferrocene compounds in a liquid 
which is suitable for delivery in vivo. 
We evaluated a panel of novel ferrocenyl-peptide bioconjugates for their anti-cancer 
potential in lung and melanoma cells. Utilizing structure-activity relationship (SAR) 
studies we found the anti-proliferative activity of the compounds tested varies 
greatly depending on the configuration of the compound. Two of the most active 
compounds N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl and methyl ester 
showed IC50 values in the nanomolar range. Cisplatin was used as a comparison and 
was found to have higher IC50 values. 
From these SAR studies the following trends were observed: 
1. 1-alkyl-1’- N-ortho- derivatives exhibited lower growth inhibition compared 
to the meta and para derivatives for the dipeptides employed  
2. Cytotoxicity of the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters, decreases with the increase of the size of the alkyl 
group incorporated (propyl < ethyl < methyl) on the ferrocene moiety 
3. The order of the amino acids in the dipeptide chain is crucial for activity, the 
trend being Gly Gly > Gly L-Ala > Gly L-Leu > Gly L-Phe. 
4. The presence of the ethynyl moiety does not result in any significant 
enhancement of the anti-proliferative effect of the N-(ferrocenyl) benzoyl and 
naphthoyl dipeptide derivatives.  
5. Replacing the ethyl ester in the previously most active, N-(6-ferrocenyl-2-
naphthoyl) glycine glycine ethyl ester, with a methyl ester further increases 
its activity. 
 
Two of the biggest factors which affect the use of chemotherapeutic drugs in a 
clinical setting are the side-effects caused by the drug and also resistance of the 
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cancer cells to the drug. We have addressed this issue by testing the most active 
compounds from the SAR studies in cell lines which have been made resistant to two 
common chemotherapeutics, cisplatin and temozolomide. We also tested the two 
most active compounds in normal human dermal fibroblast (NHDF) cells as an 
indicator of the effect which the compounds would have on healthy tissue. Results 
were favourable as one of the compounds was able to overcome the resistance and 
both compounds showed less cytotoxicity against NHDF than cisplatin. 
We analysed the effect the most active compound had on the cell cycle in lung 
cancer and melanoma cells. We observed an increase in the sub-G0 fraction which is 
indicative of apoptosis. Induction of apoptosis was confirmed using the TUNEL 
assay which detects late stage apoptotic cells. 
Due to the insolubility it was not possible to test the compounds in vivo. However, 
we tested a range of approaches to improve their solubility for future in vivo testing. 
From the results gathered, a number of conclusions can be made. It is clear that 
chemical structure of the ferrocenyl compounds plays an important role in their 
activity levels. A key aspect in the mode of action of the compound tested is the 
induction of apoptosis/necorsis. With resistance to chemotherapeutics being an 
ongoing problem in cancer treatment, the ability of a compound to overcome 
resitance to important chemotherapeutics while having a significantly lower activity 
level in normal human cells is an appealing characterstic of the tested compound. 
Finally, the issue with solubility has, at the time of writing this research thesis, been 
unsolved. However, with promising research being undertaken in the field of 
improving solubility of compounds, the future looks hopeful. 
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1.1 Cancer 
 
The term “cancer” is used to describe a disease distinguishable by the abnormal 
growth of cells which ultimately evolves into a population of cells that can invade 
tissues and spread to other parts of the body. At a molecular level, cancer cells are 
characterised by numerous alterations in multiple gene expression which leads to 
deviation from the normal program for cell division and cell differentiation [1]. The 
growth of the tumour cell population is promoted by an imbalance between cell 
replication and cell death. Over time, this aberrant growth of cancer cells progresses 
to form a malignant tumour capable of invading locally, spreading to regional lymph 
nodes and metastasising to distant organs within the body. Thus, if cancer cell 
growth is allowed to continue unchecked over a prolonged period, this disease can 
prove to be life threatening and even fatal to the patient.  
Cancer is the leading cause of death in economically developed countries and the 
second leading cause of death in developing countries [2]. Cancer is a major 
worldwide health problem that results in a huge loss of life every year. About 12.7 
new million cancer cases and 7.6 million cancer deaths are estimated to have 
occurred in 2008 world-wide [3], which despite major advances is cancer treatment 
is a rise on the 2002 figures of 10.9 million new cancer cases and 6.7 million cancer 
associated deaths [2]. By 2020, the world population is expected to have increased to 
7.5 billion; of this number, approximately 15 million new cancer cases will be 
diagnosed, and 12 million cancer patients will die [4]. 
The possibility of developing cancer is dependent on a number of risk factors which 
can vary according to the tumour location, for example, there is an increased risk of 
developing melanoma following over-exposure to ultraviolet (UV) radiation. 
Tobacco is the greatest risk factor in the development of many cancers (lung, larynx, 
oesophagus, stomach, pancreas, kidney, liver and bladder). Other factors include 
genetic predisposition, lack of balanced diet and physical activity, obesity, alcohol 
consumption, exposure to certain chemicals and gases (asbestos, benzene and radon 
gas), exposure to ultraviolet or ionising radiation, infections such as the human 
papillomavirus (HPV) and treatments such as exposure to estrogen through Hormone 
Replacement Therapy (HRT) [5]. 
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In Ireland, the most common forms of cancer in males are cancers of the prostate, 
colon, lung and lymphoma whereas among women cancers of the breast, colon, lung 
and ovaries are the most common [6]. 
Five-year survival rates can be used to gain a more accurate picture of the most 
lethal forms of cancer that affect the Irish population. Survival rates are primarily 
dependent on the location of the tumour, since this influences the ease with which 
the tumour can be detected, which in turns aids detection and treatment at an early 
stage. As a consequence, survival rates for the many distinct forms of cancer show a 
large variation. Perhaps the most striking example is the survival rate for males 
diagnosed with pancreatic cancer (5.4 %) compared to that observed for males 
diagnosed with testicular cancer (96.9 %) [6]. 
 
1.1.1 Lung Cancer 
 
Lung cancer accounted for 13 % (1.6 million) of the cancer cases and 18 % (1.4 
million) of cancer deaths in 2008. Smoking accounts for 80 % of the worldwide lung 
cancer burden in males and at least 50 % of the burden in females [7, 8]. Cigarette 
smoke exposure is a major causative factor with approximately 87 % of lung-cancer 
cases resulting from this single cause [9]. The majority of cases present with 
advanced disease and are typically associated with a less than 5 year survival 
duration. The disease can progress significantly before symptoms develop. However, 
there is generally an increase in occurrence of the common symptoms of 
expectoration and cough over time in clinical cases [10]. Lung cancers can be 
histologically classified into two main groups, non small cell lung cancer (NSCLC) 
and small cell lung cancer (SCLC) with 80 % of cases falling into the first group and 
the remaining 20 % into the second [11]. The staging of lung cancers is carried out in 
order to determine treatment regimes and to compare efficacies of new treatments 
across clinical trials. This is generally based on the (TNM) classification, where T 
represents the scale of the primary tumour, N represents the lymph node involvement 
and M represents the presence metastasis [12, 13]. 
Chemotherapy is the mainstay treatment for small cell lung cancer as surgery is often 
not an option due to most patients presenting with metastasis. Cisplatin, carboplatin, 
doxorubicin, vincristine, paclitaxel and docetaxel are among the active 
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chemotherapy drugs approved in SCLC treatment. Single agent therapy produces a 
more short lived response and so combination therapy is the standard care. Although 
response rates are high (75-80 %), most patients will suffer from relapsed disease 
[14-16]. Many single anti-cancer agents have activity against NSCLC and these 
include cisplatin, carboplatin, paclitaxel, docetaxel, vinorelbine and gemcitabine; 
however, a modest increase in response rates is seen with combinations and so 
platinum-based combinations form the standard care [17,18]. Paclitaxel or docetaxel 
in combination with cisplatin has been recommended as an option in first-line 
treatment of advanced NSCLC.  Surgical resection is more commonly employed in 
non small cell lung cancer treatment and carried out where possible [18].  
  
1.1.2 Melanoma 
 
Melanoma is a sub-type of skin cancer. One in every three cancers diagnosed 
worldwide is a skin cancer [19].  Although melanoma accounts for less than 5 % of 
all skin cancers, it is responsible for the majority of skin cancer-related mortality 
[20]. It is estimated that 76,690 will be diagnosed with, and 9,480 people will die 
of melanoma of the skin in 2013.  The overall 5-year relative survival for 2003-2009 
from 18 SEER (Surveillance, Epidemiology, and End Results) geographic areas was 
91.3 %. Fortunately, the overall death rate attributed to melanoma has not 
significantly increased since 1990 [21]. Approximately 87 % of all patients with 
melanoma are ultimately cured of their cancer, a number that is even higher with 
early detection [22]. Exposure to UV radiation is the most significant environmental 
factor contributing to melanoma [23]. Multiple studies now clearly demonstrate a 
significant correlation between tanning bed use and melanoma [24-27]. 
There are number of prognostic factors that are an indicator of the severity of the 
melanoma. The status of the regional lymph nodes is the single most important 
prognostic factor for overall survival [28, 29].
 
Metastasis to regional lymph nodes 
increases the chance of mortality from melanoma substantially. Other prognostic 
factors, in order of importance, are Breslow thickness, ulceration, mitotic rate, age, 
anatomical location of the primary tumour, and gender [30-47]. 
Breslow thickness describes a system of stratification that measured the depth of 
invasion as vertical thickness of the melanoma in millimetres [48]. As one would 
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predict, the prognosis worsens as the thickness of the melanoma increases. Using 
Breslow thickness, melanomas are commonly considered to be thin (≤1 mm), of 
intermediate thickness (>1-4 mm), or thick (>4 mm). 
Ulceration is defined pathologically as the absence of an intact epithelium overlying 
the melanoma and has emerged as a very robust predictor of prognosis.
 
Patients with 
ulcerated melanomas have a worse prognosis than those with nonulcerated 
melanomas [31-37] 
Several other factors have minor effects on prognosis. Age affects prognosis: older 
patients have a greater risk of melanoma mortality than do younger patients [47]. 
Patients with axial (trunk, head, and neck) melanomas have a worse prognosis than 
patients with extremity tumours [43]. Women have a better prognosis than men, for 
reasons that are not clear [44]. 
If identified early, surgical excision is an effective treatment of melanoma. Among 
patients diagnosed with malignant melanoma in SEER registries, wide-excision 
surgery is the primary treatment for 31 % of patients with stage I disease, 46 % of 
patients with stage II disease, 53  % of patients with stage III disease, and 9 % of 
patients with stage IV disease [49]. The importance of early detection cannot be 
underestimated. This can be seen by the 5-year survival rates. For those with 
localized melanoma, the 5-year survival rate is 98.2 %; 5-year survival rates for 
individuals with regional and distant stage disease are 61.7 % and 15.2 %, 
respectively [49]. 
The reason for the poor prognosis to melanoma which has metastasized is the low 
sensitivity to systemic treatments. These treatments include chemotherapy, 
immunotherapy and radiation therapy. 
The most widely used single chemotherapeutic agent is dacarbazine (DTIC). DTIC is 
a non classical alkylating agent whose metabolite methylates DNA to exert its 
cytotoxic activity [50]. Overall response rates are low at 10 – 20 %, with complete 
remission observed in < 5 % of patients [51]. Such poor responses to single agent 
chemotherapy led to investigations into combinations of chemotherapeutics. The 
most common combined chemotherapy regimens used as standard for the treatment 
of metastatic melanoma are the Dartmouth regimen and CVD regimen. The 
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Darthmouth regimen is a four-drug combination comprising cisplatin (3a), 
carmustine (fig. 1a), dacarbazine (fig. 1b) and Tamoxifen (fig. 5a). The CVD 
regimen is a combination of cisplatin, vinblastine and dacarbazine [52]. In the 
randomized experiments to date, it has been reported that no drug or combination of 
therapies is superior to dacarbazine alone [52]. Several randomised, controlled trials 
have compared single-agent dacarbazine with combined chemotherapy. The results 
from these studies demonstrated that dacarbazine is as effective as combined 
chemotherapy regimens, with an advantage that it is better tolerated and with fewer 
side-effects [53-55]. Dacarbazine is also convenient to administer and inexpensive 
[53]. Further testing and randomised trials have shown that the Dartmouth regime 
has actually little or no benefit compared to the single agent dacarbazine treatment. 
The associated toxicity with the treatment is so severe that high fatality rates were 
recorded. The response rate of the regimen was short and long-term remissions from 
the disease were rare [56]. Although the benefits of dacarbazine are modest, it 
remains the reference treatment for Stage IV melanoma and is the only 
chemotherapeutic agent approved by the US FDA for the therapy of metastatic 
melanoma.  
Over the last decade, significant progress has been made in the systemic treatment of 
stage IV melanoma. It has long been suspected that defects in the host immune 
system play a major role in the pathway for melanoma tumorigenesis and metastasis. 
Regulatory pathways that limit the host’s immune response have become a 
particularly interesting molecular target for treatment of metastatic melanoma. 
Cytotoxic T-lymphocyte-associated antigen (CTLA-4) has been described as an 
immune checkpoint molecule that downregulates the pathways of T cell activation 
[57,58]. Ipilimumab is a monoclonal antibody that blocks CTLA-4 to promote 
antitumor immunity [58]. In 2004, a randomized, controlled, multicenter phase III 
trial was initiated for patients with unresectable stage III or stage IV melanoma 
whose disease had progressed while receiving standard systemic therapy [59]. This 
was the first randomized, controlled trial to show a significant improvement in 
overall survival for patients with metastatic melanoma treated with systemic therapy, 
increasing the median overall survival of 6.4 months for the gp100 (a 
synthetic peptide cancer vaccine) vaccine alone to 10.0 months when given in 
combination with the Ipilimumab [59]. 
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Another molecular pathway that has been shown to play a role in the progression of 
melanoma is the mitogen-activated protein kinase pathway, which is regulated by the 
protein, V-raf murine sarcoma viral oncogene homolog B1 (BRAF). Mutations in 
BRAF are found in 40 % - 60 % of cutaneous melanomas and result in constitutive 
activation of the mitogen-activated protein kinase pathway [60,61]. Approximately     
90 % of these mutations are BRAF V600E, which is effectively inhibited by the 
monoclonal antibody vemurafenib [62]. At 6-month interim analysis, vemurafenib 
showed a statistically significant improvement in overall survival compared with 
DTIC (84 % vs 64 %). In addition to an improvement in overall survival, 
vemurafenib also showed a significant improvement in tumor response rate. Forty-
eight percent of patients had a confirmed, objective response to vemurafenib 
compared with only a 5 % response rate for patients treated with DTIC [63]. In 2012, 
the FDA approved ipilimumab and vemurafenib for the treatment of stage IV 
melanoma. 
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   (a)         (b) 
Figure 1: Chemical structure of 2 of the chemotherapeutics administered as part of 
the dartmouth regimen, carmustine (a) and dacarbazine (b) [52]. Cisplatin (fig 3a) 
and tamoxifen are the remaining chemotherpautic agents which are also 
administered. 
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1.2 Bioorganometallic Anticancer Drugs 
 
Bioorganometallics is the study of biologically active organometallic compounds.  
Organometallic compounds are defined as a metal complex containing at least one 
direct, covalent metal-carbon bond [64]. Bioorganometallic chemistry developed as a 
rapidly growing and maturing area which links classical organometallic chemistry to 
biology, medicine, and molecular biotechnology. The advantages of organometallics 
are that they have great structural variety and have more diverse stereochemistry 
than organic compounds. Furthermore, they are kinetically stable, usually uncharged, 
and relatively lipophilic and their metal atom is in a low oxidation state. Because of 
these properties they offer opportunities for the design of novel classes of anticancer 
drugs [64]. 
 
1.2.1 Metallocenes 
  
In 1973, Ernst Otto Fischer and Geoffrey Wilkinson were awarded the Nobel Prize 
in Chemistry for their pioneering work performed independently on the chemistry of 
the organometallic, so called “sandwich compounds”. Metallocenes are subset of the 
larger group of compounds known as sandwich compounds [65]. Metallocenes are 
defined, by the Internation Union of Pure and Applied Chemistry IUPAC, as 
“Organometallic coordination compounds in which one atom of a transition metal 
such as iron, ruthenium or osmium is bonded to and only to the face of two 
cyclopentadienyl [η5-(C5H5)] ligands which lie in parallel planes”[66]. The term 
metallocene was coined after the discovery of the structure of ferrocene and so led to 
the work on other similar, metal-based compounds. As soon as the metallocenes 
were discovered, the medical potential offered by this new family of compounds 
rapidly came under study and became the subject of a number of publications [67-
69]. In the mid-1970s, Kopf-Maier was the first to study the effect of various 
metallocenes, including those of ferrocene, on the growth of ascites in mice, the 
model available at that time for in vivo testing of the effectiveness of molecules on 
the growth of cancer cells. The results obtained showed a moderate effect for the 
salts of ferriciniums but only in high dose [68,70,71]. 
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  (a)      (b) 
 
 
 
 
 
 
           (c)        
Figure 2: Chemical structures of examples of metallocenes. The archetypal 
metallocene, ferrocene (a) [46]. A derivative of tamoxifen which has ferrocene 
incorporated in its structure, ferrocifen (b) [131]. Titanocene dichloride (c) [181].  
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1.3 Chemotherapy 
 
Chemotherapy has become one of the cornerstones of modern cancer treatment. The 
link between chemical compounds and their anti-cancer effects was initially found in 
the autopsies of allied soldiers who were exposed to mustard gas after a ship holding 
30-35 kg of mustard gas bombs was blown up after an air raid in Italy, dispersing the 
gas [72]. Autopsy results showed a suppression of growth of lymphoid and myeloid 
tissue. Trials were then set up using a suitable pharmaceutical derivative which 
showed a reduction in tumour mass for the patient; however the effect only lasted for 
only a few weeks [72]. The next step, and first non-accidental step, to using 
chemicals to treat cancer was the antifolates. Antifolates were used in the treatment 
of acute lymphoblastic leukemia, and are still used in the form of clinically approved 
methotrexate. The antifolates function by interfering with the production of purines 
and pyrimidines and therefore with DNA synthesis [73]. Since those early 
experiments, interest in chemopharmaceuticals as a cancer treatment has come on in 
leaps and bounds. In ~65 years whole families of chemotherapeutics have been 
developed and the search for more improved drugs is ongoing. The latest generation 
of chemotherapeutic agents are those involved in targeted therapy. Up until this point 
most chemotherapeutics were purely cytotoxic agents which attempt to find a 
significant balance in favour of being toxic to cancer cells over healthy cells. 
 
1.3.1 Cisplatin 
 
Platinum drugs are included in approximately 50–70 % of therapeutic schemes used 
to treat cancer patients [74,75]. Cisplatin (fig. 3a) is highly effective in the treatment 
of testicular and ovarian cancers and is also widely employed for treating bladder, 
cervical, head and neck, oesophageal and small cell lung cancer [76]. The 
biochemical mechanisms of cisplatin cytotoxicity involve the binding of the drug to 
DNA and non-DNA targets and further induction of cell death through apoptosis, 
necrosis or both within the heterogeneous population of cells that forms a tumoural 
mass [77]. Although cytotoxicity of cisplatin is primarily attributed to its reactivity 
against DNA and subsequent lesions, more than 80 % binds to nucleophilic sites of 
intracellular constituents like thiol containing peptides, proteins, replication 
enzymes, and RNA [78,79-81].  
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Cisplatin induces cell cycle arrest followed by apoptosis. There are two main 
checkpoints (G1/S and G2/M) in the cell cycle that screen the proper evolution of the 
process in order to avoid the acquisition and accumulation of mutations [82]. In the 
event of DNA damage, the cell cycle will be arrested to help the function of the 
repair machinery. The G1/S checkpoint allows DNA restoration before replication, 
and G2/M facilitates the repair of DNA damaged during S or G2 steps to prevent its 
segregation into daughter cells [83]. G2 arrest seems to be essential to trigger 
cisplatin-induced cell death [84]. It is commonly accepted that futile attempts to 
repair cisplatin-DNA adducts induce cytotoxic processes that finally end up in the 
triggering of apoptosis [85]. It has also been reported that, in other cell lines, 
particularly those with resistance to the drug, cisplatin produces characteristic 
features of necrosis, which is considered a mode of cell death due to general cellular 
machinery failure [86-88]. Moreover, it has been found that necrotic and apoptotic 
cell death may take place together in the same population of cisplatin-treated cells 
[89].  
Resistance to cisplatin is generally considered a multifactorial phenomenon, which is 
mainly due to (i) reduced drug accumulation, (ii) inactivation by thiol containing 
species, (iii) increased repair of platinum-DNA adducts, and (iv) increase of cis-
diamminedichloroplatinum (cis-DDP) adducts tolerance and failure of cell death 
pathways. These resistance mechanisms are cell line-dependent so that a particular 
tumour may exhibit one, two or even all the above-mentioned mechanisms [90,91]. 
Some tumours such as colorectal and non small lung cancers are initially resistant to 
cisplatin while other like ovarian and small cell lung cancers easily acquire 
resistance to the drug [92] 
 
1.3.1.1 Cisplatin Derivatives 
 
With cisplatin resistance becoming a problem and in an effort to reduce toxicity a lot 
of research was dedicated to finding derivatives to overcome these problems. In the 
mid 1980s, after many failed derivatives, carboplatin showed promising results in 
clinical trials [93].  
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1.3.1.2  Carboplatin 
 
Carboplatin (Fig. 3b) contains the {cis-Pt(NH3)2} active fragment of cisplatin, but 
the two chloride leaving groups are replaced by a bidentate dicarboxylate. The 
biological mechanism of action of carboplatin appears to be analogous to that of 
cisplatin with the induction of DNA adducts. The spectrum of cancers that can be 
treated is also identical. The change of leaving group reduces the activity of the 
agent somewhat, however. While it is as effective in ovarian cancer, it is less potent 
against testicular, head, and neck cancers. Correspondingly, the side effects are less 
severe. Consequently, cisplatin has tended to remain the agent of choice, with 
carboplatin used when there is a clinical need to minimize the platinum drug side 
effects because of other medical conditions [94]. 
A major advantage of carboplatin over cisplatin was the reduction of nephrotoxicity, 
neurotoxicity and gastrointestinal toxicity. However, it does have its own toxicities, 
mainly myelosupression [95]. For that reason carboplatin is not given to patients 
with an already weakened immune system. The primary treatment regime which 
utilizes carboplatin is for ovarian cancer, and was approved for such in 1989 [96]. 
Despite overcoming many of the toxicity issues associated with cisplatin, resistance 
remains an issue due to both drugs having the same mode of action.  
 
1.3.1.3 Oxaliplatin 
 
Another platinum drug, oxaliplatin (Fig. 3c) was the third to achieve clinical 
acceptance. The clinical advantage of oxaliplatin is that it has a different spectrum of 
activity: in particular, it is effective against colorectal cancer, a disease not treatable 
using cisplatin or carboplatin [96]. Moreover, oxaliplatin is active against some 
cisplatin-resistant cancers. The precise biological reasons for the difference in 
spectrum of activity and the ability of this agent to circumvent some cisplatin 
resistance mechanisms remain to be fully elucidated. 
Oxaliplatin was developed in the late 1970s as a further attempt to overcome some of 
the problems associated with cisplatin, namely nephrotoxicity and resistance. It is a 
member of a family of derivatives known as the “dach” family, named because they 
were constructed by replacing the amine radicals of cisplatin with a 1,2-
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diaminocyclohexane radical [97]. Though many showed significant anti-tumour 
activity, oxaliplatin was the only one which was sufficiently water soluble [98]. 
Currently, oxaliplatin is used in conjunction with 5-fluorouracil and often folinic 
acid in the treatment of colorectal cancer [99,100]. The toxicities of cisplatin and 
carboplatin are overcome using oxaliplatin; however there is still a dose-limiting 
toxicity for cumulative sensory peripheral neuropathy that is exacerbated by 
exposure to cold, although this is more easily reversed compared to cisplatin 
[101,102].  
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  (a)    (b)     (c) 
Figure 3: Clinically established anti-cancer platinum complexes cisplatin (a), 
carboplatin (b) and oxaliplatin (c) [75] 
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1.3.2 Ferrocene 
 
Ferrocene (fig. 4) is perhaps the quintessential organometallic molecule, indeed the 
elucidation of this sandwich compound gave rise to the field of organometallic 
chemistry. First discovered in 1951, ferrocene is an organometallic compound owing 
its name to its similarity in reactivity to benzene [103]. The elucidation of the 
structure also gave rise to the terms “metallocene” and “sandwich compound” [104]. 
Some of the properties of ferrocene have lent themselves to its incorporation into a 
variety of applications. Its stability and reversible redox properties make it an ideal 
constituent of many biologically active compounds, amongst them being 
antimalarial, anti-fungal, antibacterial and of particular interest, anti-cancer agents. 
The anticancer potential of ferrocene derivatives was first studied in the late 1970s, 
when Brynes and co-workers reported the antitumour activity of ferrocenyl 
compounds bearing amine or amide groups against lymphocytic leukemia [105]. 
Since then, several types of ferrocenyl compounds have been synthesised and 
evaluated in terms of anticancer properties. The discovery of the cytotoxic properties 
of ferricinium salts on Ehrlich ascite tumours by Köpf and Köpf-Maier [106,107] 
was an early breakthrough for the subsequent development of novel preparations of 
this class of anticancer agent. 
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Figure 4: Chemical structure of 
ferrocene [46]. 
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1.3.2.1 Mode of Action 
 
Although ferrocene itself is not cytotoxic, its derivatives, including ferrocinium 
species, are cytotoxic. Their potential to induce the formation of reactive oxygen 
species (ROS), such as hydroxyl radicals, which are capable of damaging DNA and 
other biomolecules is considered to be important in their mode of action.  
The biological processes controlling carcinogenicity and cancer progression are 
diverse in the extreme and only partially understood even at this present time. ROS 
and associated free-radical reactions are significant contributors to the overall 
interplay of these processes [108–110].  
Reduction of O2 in the respiring aerobic cell produces O2
 
derivatives which in turn 
produces hydrogen peroxide and the highly destructive hydroxyl free radical (

OH). 
In the healthy organism these species will be modulated by the detoxifying action of 
a variety of cell protective enzymes, such as superoxide dismutase (SOD), catalase, 
glutathione (GSH) and peroxidase, mobilised by the host’s defence mechanisms 
[111,112]. Under normal physiologic conditions, cells control ROS levels by 
balancing the generation of ROS with their elimination by a scavenging system 
[113]. However, under oxidative stress conditions, excessive ROS can damage 
cellular proteins, lipids, and DNA, giving rise to fatal lesions in cells that, in turn, 
contribute to many human diseases, including cancer [114-118]. 
If kept under control, reactive oxygen species, such as hydrogen peroxide, may in 
fact perform a vital role in sustaining homeostasis, and thus healthy equilibrium, 
through induction of apoptosis of detrimental cells. If left unchecked, on the other 
hand, the very same species can be found to operate against the host’s well being. 
Strongly reduced SOD activity, for example, was observed in many cancer cells 
[112], and the generation of superoxide and secondary free radicals in elevated 
concentrations may initiate pathological reactions, as these species bind to the cell’s 
DNA with resultant replication errors during the mitotic stage [110]. Carcinogenesis 
may thus be triggered. 
Most cancer cells both in isolated form and in tissue exhibit enhanced ROS 
production [119]. Since they function with a heightened basal level of ROS, cancer 
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cells are more vulnerable to oxidative stress than healthy cells [3]. Exogenous 
compounds inducing production of ROS or other radicals can potentially be used as 
anticancer drugs.  
Jaouen and co-workers have developed an anticancer drug, hydroxyferrocifen, a 
ferrocenyl analogue of 4-hydroxytamoxifen [120]. Among all the ferrocene derived 
cancer therapeutics, the ferrocifens are probably the most widely studied, showing 
very promising results for breast cancer [121,122]. This compound is converted in 
cells into toxic quinone methide [123,124] which alkylates GSH, thus inhibiting the 
antioxidative system of cells. The ferrocene fragment in this prodrug facilitates 
formation of the quinone methide rather than acts itself as a catalyst of ROS 
generation. It appears that the reversible and mild oxidation chemistry of ferrocene 
allows it to act as an intramolecular oxidant of a distant phenol group, when linked 
by a conjugated system, [125] thereby lowering the oxidation potential necessary for 
toxic quinine methide formation. These compounds are selectively active on cancer 
cells, with approximately 100 times less activity on normal cells, [123] probably due 
to their prodrug features. 
 
1.3.2.2 Previously synthesized ferrocene-based compounds 
 
The quest for new and improved chemotherapeutic agents is constant. With the early 
work of Kenny et al., N-ferrocene peptide derivatives containing amide NH groups 
there has been an ongoing search for improvements which can be made structurally 
to enchance the anti-cancer activity of the compound. The aim of this research is to 
examine the latest generation of derivatives and see if any improvements have been 
made by way of enhanced anti-proliferative activity across a panel of cell lines and 
to identify potential modes of action that account for this activity. The natural 
progression for chemotherpautics which show high levels of activity in vitro is to test 
it in a live animal study, in vivo. For this reason, an attempt to make a solution which 
would be acceptable to be given intravenously was attempted. 
Previous studies within the group have been carried to evaluate the in vitro activity 
of novel ferrocenyl benzoyl amino acid and dipeptide esters. N-{ortho-(ferrocenyl) 
benzoyl} glycine ethyl ester was initially tested for its in vitro anti-proliferative 
activity. This compound was found to be cytotoxic, whereas the starting material, 
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ortho-ferrocenyl ethyl benzoate, was completely inactive against the cell line. 
Therefore, other derivatives were prepared and evaluated for their anticancer activity 
against H1299 lung cancer cells. The dipeptide derivative N {ortho-(ferrocenyl) 
benzoyl} glycine glycine ethyl ester was shown to have an improvement in activity, 
while N-{ortho-(ferrocenyl) benzoyl} glycine L-alanine had an even greater 
improvement in activity. The N- {meta-(ferrocenyl) benzoyl} glycine L-alanine ethyl 
ester and N-{para-(ferrocenyl)- benzoyl} glycine L-alanine ethyl ester were also 
tested and gave similarly high levels of activity [126-130]. As an extension of this 
study we now report the synthesis and structural characterization of novel 1-alkyl-1’-
N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters. These novel 
derivatives differ from the N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters by having an alkyl moiety on the previously unsubstituted 
cyclopentadiene ring. a series of novel 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters 64–99 were prepared by coupling alkyl 
ferrocenyl benzoic acids to the dipeptide ethyl esters using the conventional N-(3-
dimethylaminopropyl)-N’- ethylcarbodiimide hydrochloride (EDC) and 1-
hydroxybenzotriazole (HOBt) coupling protocol.  
Incorporation of electron donating groups is a well known strategy to lower 
oxidation potentials of ferrocene moieties [131]. Thus, the incorporation of the 
various alkyl chain groups (electron donating groups) to the unsubstituted 
cyclopentadiene ring of the N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters should improve the cytotoxicity of these derivatives. In addition, the 
alkyl chain should also increase the lipophilicity of the reported derivatives [126-
130]. 
To date we have shown that the replacement of the conjugated linker of N-
(ferrocenyl) benzoyl dipeptide esters with a naphthoyl linker leads to an 
improvement in antiproliferative of the compound [132-134]. From the series of N-
(ferrocenyl) naphthoyl amino acid and dipeptide ethyl esters reported, the N-{6-
(ferrocenyl)-2-napthoyl} glycine glycine ethyl ester displayed an IC50 value of 0.13 
± 0.01 μM in the H1299 lung cancer cell line [134]. From the promising results 
obtained from the 1-alkyl-1’-N-para, N-meta and N-ortho- (ferrocenyl) benzoyl 
dipeptide esters 64–99. It has been clearly demonstrated in the SAR study of the 1-
alkyl-1’ derivatives that employing the incorporation of a methyl derivative to the 
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unsubstituted cyclopentadiene ring enhances the anti-proliferative effect of the 
ferrocenyl dipeptide bioconjugates relative to the N-(ferrocenyl) benzoyl dipeptide 
derivatives in the H1299 lung cancer cell line [126-130]. This SAR study involves 
the biological evaluation of the incorporation of an ethynyl moiety between the 
ferrocene moiety and the conjugate linker. Furthermore, the incorporation of L-
leucine and L-phenylalanine into the dipeptide chains have been shown in the 
preliminary screen of the 1-alkyl-1’ derivatives (64-69) to display low percentage 
growth inhibition values in H1299 lung cancer cell line. The synthesis of the new 
ferrocenyl conjugates involved Sonogashira coupling of an ethynyl ferrocene to three 
bromo acylated acids to generate para-(ferrocenyl) ethynyl benzoic acid, naphthoic 
acid and 2-furanoic acid. 
In a further extension to ferrocenyl benzoyl and naphthoyl bioconjugates reported, a 
new library of ferrocenyl based bioconjugates 105-138, which consist of four key 
moieties (i) an electroactive core (ii) a -C≡C- moiety (iii) three different aromatic 
linkers and (iv) and a series of amino acid and dipeptide esters are now reported 
here. The incorporation of the -C≡C- moiety between the ferrocene moiety and the 
aromatic spacer and the use of three different aromatic rings are attempts to further 
improve the cytotoxicity of the previously prepared N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters.  
A series of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and dipeptide 
esters were prepared and structurally characterized. Each novel compound 
incorporated an electroactive ferrocene core, a -C≡C-, a conjugated aromatic linker 
and a dipeptide chain with each part exerting a specific effect on biological activity. 
The ferrocene moiety is required for the possible production of hydroxyl radicals, the 
-C≡C- and conjugated aromatic linkers facilitates this process by lowering the redox 
potential of the ferrocene and the peptide fragment can interact with other molecules 
via hydrogen bonding.  
For the synthesis of para, meta and ortho-(ferrocenyl) benzoic acid the synthetic 
protocol involved the diazonium coupling of ferrocene to 2, 3, 4-ethylamino 
benzoate followed by basic hydrolysis [126-130]. The use of the diazonium coupling 
reaction in the preparation of the monoarylferrocenes derivatives proceeds with a 
31 
 
low degree of regiocontrol and produces intractable mixtures of mono-, di- and poly-
arylferrocene derivatives with low yields of less than 8% for the desired 
monoarylferrocene derivatives. For the synthesis of the ethynyl analogues 105-138, 
the synthetic protocol involved the use of Sonogashira cross coupling of ethynyl 
ferrocene to three bromo acylated acids to generate para-(ferrocenyl) ethynyl 
benzoic acid, 6-(ferrocenyl) ethynyl-2-naphthoic acid, and 5-(ferrocenyl) ethynyl-2-
furanoic acids. In this coupling reaction, yields greater than 60% were obtained. 
These high yields are largely due to the fact that Sonogashira cross coupling is a 
substrate specific reaction between an alkyne and an aryl halides employed in the 
coupling reaction which involves the use of palladium catalyst and copper iodine co 
catalyst. 
The acid phosphatase assay was chosen as the method to determine cell growth. The 
assay is based on the hydrolysis of the p-nitrophenol phosphate by intra-cellular acid 
phosphatises in viable cells to produce p-nitrophenol. The assay shows higher 
sensitivity and reproducibility in comparison to cell proliferation assays based on the 
reduction of tetrazolium salts. 
Previous work within the group have identified ferrocenyl compounds have an effect 
on the cellular cycle of cancer cells. For this reason a cell cycle assay was used 
utilizing propidium iodide as a stain which can measure DNA content which changes 
at each phase of the cell cycle. Results from cell cycle analysis have suggested that 
apoptosis/necrosis plays a role in the activity of these ferrocenyl compounds. The 
TUNEL assay was therefore used to confirm or deny this as it is a common method 
for detecting DNA fragmentation that results from apoptotic signaling cascades. 
 
1.3.2.3 Ferrocifen 
 
One of the big successes of ferrocene-based anticancer drugs has been a series of 
ferrocene derivatives of Tamoxifen (fig. 5a) which have emerged from the 
laboratories of Jaouen [124]. Tamoxifen is an organic drug that acts on the estrogen 
receptor and has had a very significant impact in the treatment of breast cancer. 
Approximately 30 % of breast cancer patients fail to respond to tamoxifen treatment. 
In part, this is due to the presence of two different estrogen receptors (ERα and ERβ) 
in humans; tamoxifen is effective only against breast cancers which are ERα 
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positive. The ferrocifens (5b) are agents in which one phenyl ring of tamoxifen is 
replaced with ferrocene. These agents are highly active against breast cancer cells 
that are ERα negative (ERβ positive) as well as breast cancers that are ERα positive. 
Ferrocifens are the first molecules shown to be active against both hormone-
dependent and hormone-independent breast cancer cells [125].  
The role of the ferrocene is believed not to be solely restricted to that of a structural 
unit. Rather, it appears that the ferrocene could be oxidised to ferrocenium in the cell 
and subsequently cause oxidative damage through Fenton-type mechanisms [135]. 
The activity of ferrocenyl compounds depends on the oxidation state of iron in the 
ferrocene moiety. The mechanism of ferrocifen as one of the Fe(II) compounds has 
been studied and the results indicate that the ferrocifens act by changing the 
conformation of the receptor protein [136].  
In addition, when ferrocifen binds to ERβ, an ‘oxidant/antioxidant’ mechanism may 
occur. The ferrocifen–ERβ complex is thought to dimerize and attach itself to a 
particular region of DNA, and Fe
2+
 complexes are known to be oxidized to Fe
3+
 by 
O2, leading to the generation of highly reactive •OH radicals [137]. These radicals 
could damage the DNA strand close to the binding site, thus explaining the observed 
antiproliferative effect in connection with the ERβ receptor [138]. DNA damage 
produced by exposure to ferrocifens was observed [139]. Currently, there is a library 
of around 300 ferrocene complexes which have been tested for their antiproliferative 
effect mainly on breast cancer and prostate cancer cells. [140-146]. Recently, 
Jaouen’s group have developed a method of effectively solubilising the most active 
compounds in the library and in vivo testing has shown promising results [147]. 
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   (a)     (b) 
Figure 5: Chemical structure of Tamoxifen (a) dervived anti-cancer compound, 
ferrocifen (b) in which the aromatic β ring of Tamoxifen is replaced by a ferrocene 
moiety [140]. 
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1.3.3 Other Metal-Based Chemotherapeutics 
 
1.3.3.1 Gallium 
 
Toxicities and anti-tumour activities of gallium salts were described as early as 1971 
[148,149]. Gallium nitrate, a simple gallium salt, can be considered a ‘first 
generation’ gallium compound that was investigated for its anticancer activity in 
humans [150]. This drug is, therefore, the standard against which newer gallium 
compounds are compared. In Phase II clinical trials conducted to evaluate the 
spectrum of its antineoplastic activity, gallium nitrate was administered to patients 
with a variety of different cancers, of which it was found to have antineoplastic 
activity primarily against advanced bladder cancer and non-Hodgkin’s lymphoma 
[151-154]. In these malignancies, significant responses to gallium nitrate were seen 
in patients whose tumours had relapsed or failed to respond to conventional 
chemotherapy. Encouraged by these findings, a limited number of clinical trials 
ensued in which gallium nitrate was administered in combination with other 
chemotherapeutic agents (vinblastine, ifosfamide, 5-fluorouracil, mitoguazone, 
etoposide and hydroxyurea) to patients with bladder cancer or non-Hodgkin’s 
lymphoma. These trials demonstrated that gallium nitrate could be safely combined 
with other drugs with a good clinical outcome [151-153].  
A phase II trial yielded a disappointing objective response rate of only 3 % in 
patients with advanced malignant melanoma, discouraging further evaluation [154]. 
Gallium nitrate showed notable anticancer activity in phase II trials in lymphoma and 
bladder cancer [155]. However, the applicability of gallium nitrate as an anticancer 
drug was questioned by nephrotoxicity (in the case of short infusions) and occasional 
severe optical neuropathy (in the case of continuous infusions). An improved 
therapeutic index was expected to result from prolonged exposure to low steady-state 
plasma gallium concentrations, but attempts to accomplish this with oral 
administration of gallium chloride yielded unsatisfactory results because of 
insufficient bioavailability [156]. Complexing gallium with suitable chelators has 
been pursued to stabilise gallium against hydrolysis, which is the major impediment 
for intestinal absorption, and to facilitate membrane permeation, namely tris(8-
35 
 
quinolinolato)gallium(III) (KP46) and tris(3-hydroxy-2-methyl-4H-pyran-4-
onato)gallium(III) (gallium maltolate).  
The concentration required to inhibit 50 % of growth (IC50 value) of KP46 in a 
variety of melanoma, ovary, breast, colon and lung cancer cell lines in vitro ranged 
from 0.85 to 10.4 μM [157], which is much lower than that reported for gallium 
nitrate. In addition, the combination of KP46 and platinum drugs acts synergistically 
to inhibit the proliferation of ovarian and colon cancer cell lines in vitro [158]. In a 
Phase I/II clinical trial of oral KP46 in patients with solid tumours (renal, ovarian, 
stomach and parotid gland), the drug was found to be well-tolerated over a dose 
range of 30 to 480 mg/m
2
 daily for 14 days; no significant dose-limiting toxicities 
were observed [159,160]. Responses to treatment were seen in three out of four 
patients with renal cancer [159,160]. The treatment of renal cancer is challenging 
since this disease does not respond to conventional chemotherapy or to gallium 
nitrate; hence, the initial activity of KP64 in this malignancy is noteworthy and 
should be further explored. Clinically achievable concentrations of KP46 proved to 
be highly effective in melanoma cells from primary explants of cutaneous and lymph 
node metastases. For KP46, there is preliminary evidence for activity in renal cell 
carcinoma, with one partial response and two disease stabilisations for up to 11 
months [161]. Clinical activity in this malignancy, which is otherwise largely 
chemoresistant probably due to effective detoxification mechanisms, is 
unprecedented in the development of anticancer metal compounds. KP46 has yet to 
progress to phase II trials, in which it could qualify for combinations with other 
drugs (such as cisplatin) for increased effect. There are ongoing investigations on the 
anti-tumor mechanism of action and key targets of KP46, to make the clinical 
development of KP46 more straightforward. Antitumour activity is thought to be by 
interaction with ribonucleotide reductase followed by impairment of the catalytic 
activity of the enzyme [162] 
Gallium maltolate is a gallium compound that has been developed for oral use. 
Allamneni et al. reported that following oral administration of gallium maltolate to 
normal subjects, gallium in the circulation is found bound to transferrin, the iron 
transport protein, with very little of it unbound [163]. In another study utilizing a 
panel of lymphoma cell lines, gallium maltolate was shown to induce apoptosis at 
earlier time points and at significantly lower concentrations than gallium nitrate 
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[164]. Evidence that gallium maltolate has antineoplastic activity in humans was 
recently provided by Bernstein et al. [165]. These investigators reported a patient 
with advanced hepatocellular carcinoma that had failed to respond to treatment with 
the drug sorafenib. Treatment of this patient with 1500 mg/day of oral gallium 
maltolate resulted in marked clinical improvement of the patient’s symptoms and a 
significant reduction in the size of the hepatic mass, as measured by imaging studies 
of the liver [166]. 
Both complexes show a high bioavailability in animal models when administered via 
the oral route [167,168] and are more potent inhibitors of tumour cell proliferation in 
vitro than gallium salts [169,170]. No dose-limiting toxicities were encountered in 
phase I studies with either gallium maltolate or with KP46 [169, 170], reflecting the 
higher than expected tolerability of these compounds.  
 
1.3.3.2 Titanium 
 
The pioneering work of Köpf and Köpf-Maier in the early 1980s showed the 
antiproliferative properties of titanocene dichloride, [TiCp2Cl2], and the compound 
was studied in phase I clinical trials in 1993 [171–173]. Although the compound 
advanced as far as stage II clinical trials in patients with breast metastatic carcinoma 
[174] and advanced renal cell carcinoma [175], low levels of activity discouraged 
further trials. The compound was found to bind more weakly to DNA bases than 
cisplatin with the hard Ti
IV
 ion showing higher affinity to the phosphate backbone of 
DNA [176]. The main disadvantages of titanocenium compounds, which may have 
led to the low activities in the clinical phase II trials, are their poor solubility in 
aqueous media and their hydrolytic instability under physiological conditions [174].  
Since that time there has been a renewed interest in titanocene with research groups 
developing derivatives with amino acids [177,178], amide functionalized 
titanocenyls [179], titanocene derivatives with alkylammonium substituents on the 
cyclopentadienyl rings [180–182], steroid-functionalized titanocenes [183], and 
alkenyl-substituted titanocene or ansa-titanocene derivatives [184–186]. One such 
agent is Titanocene Y, which contains methoxyphenyl substituents of the Cp rings 
which confer the agent with higher potency [187]. The anti-proliferative activity of 
titanocene Y and other titanocenes has been studied in 36 human tumour cell lines 
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[188] in vitro and ex vivo showing that renal cancer is a major target for this novel 
class of titanocenes. They also showed signiﬁcant activity against ovarian, prostate, 
cervix, lung, colon and breast tumours [189]. 
Ex vivo experiments demonstrated that titanocene Y has signiﬁcant cytotoxic effects 
comparable to cisplatin when tested on explanted renal cell, ovarian, non-small cell 
lung and colon tumours [190]. Titanocene Y induced cell death in freshly explanted 
human breast cancer cells and led to reduction of tumour volume in a MCF-7 human 
breast cancer xenograft mouse model. During exposure, no mouse was lost, 
indicating low toxicity of the agent [191]. In human epidermoid cancer cells 
treatment with titanocene Y induced caspase-3 and -7 dependent apoptosis in vitro 
and led to reduction of tumour growth in an A431 xenograft model of epidermoid 
cancer in vivo [192]. In the same studies, A431 cancer cells were stained with 
Annexin V and propidium iodide to detect early and late apoptotic cells, confirming 
that cell death occurs via apoptosis. Further in vivo tests with xenografted Caki-1 
tumours in mice revealed a significant and dose dependent inhibition of tumour 
growth with no severe side effects at non lethal doses [193]. Presently titanocene Y 
is under investigation for its potential ability to overcome resistance to conventional 
anti-cancer drugs and to identify the main mechanisms of action, focusing on the 
apoptotic pathways through which titanocene Y causes apoptosis. 
 
1.3.3.3 Ruthenium 
 
Ruthenium-based compounds have attracted the interest of many researchers who 
envisaged the possibility of using this metal to develop innovative characteristics in 
new compounds to treat tumours with a selective cytotoxicity for cancer cells [194, 
195]. Ruthenium complexes, including some organometallics, have shown 
interesting anticancer properties in vivo and may represent new and efficient 
therapeutic agents to be used as alternative to platinum drugs [196]. The successful 
clinical phase I trials of indazoliumtrans-[tetrachlorobis(1H-indazole)-ruthenate(III)], 
KP1019 (fig 6b)  and imidazolium trans-[tetrachloro-(S-dimethyl sulfoxide)(1H-
imidazole)ruthenate(III)], NAMI-A (Fig. 6a) two coordination complexes based on 
ruthenium, has led to considerable interest in anticancer drugs based on this element 
[197,198].  
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In general, compared to platinum-based drugs, ruthenium drugs are less toxic and are 
also active in tumours that do not respond well to the platinum drugs. Ruthenium is 
particularly attractive as the ligand exchange kinetics in its complexes can be similar 
to those of platinum complexes.  
The first ruthenium agent to enter clinical trials was NAMI-A [199,200]. That this 
drug has made it to clinical trials is quite remarkable because it is not very active 
against cancer cell lines, which are the usual first screen for activity (failed the NCI 
cell line panel screen) [201]. While NAMI-A can bind to DNA, this is not believed 
to be the source of its biological action. Rather, NAMI-A seems to act as an anti-
angiogenic and anti-invasive agent. Its anti-angiogenic properties may relate to the 
ability of NAMI-A to scavenge Nitric Oxide (NO) produced by epithelial cells. The 
anti-invasive properties appear to be a result of its interaction with extracellular or 
external cell membrane receptor proteins. Today NAMI-A is studied for the use as a 
second line therapy in the metastatic NSCLC in combination with gemcitabine. 
Although the study is still ongoing, preliminary data of dose finding show the 
possibility to treat these patients with the combination NAMI-A and gemcitabine. 
The main toxicities are ﬂebitis at the injection site, for which reason the drug is 
infused through a central venous catheter, general malaise and cutaneous blister 
formation [202]. 
The second of the ruthenium agents is indazolium trans- [tetrachloro-bis(1H-
indazole)ruthenate(III)] (KP1019) (fig.6b) [197]. Despite its structural similarity to 
NAMI-A, this agent is a cytotoxin which is active against primary tumours, and is 
being investigated for activity against colorectal cancers. The agent causes apoptosis 
via the mitochondrial pathway and is believed to act as a pro-drug with the actual 
active species as yet not identified. Transferrin is normally used to transport iron 
centres into the cell and is over-expressed in cancer cells. It is believed that the 
ruthenium complex is transported into cells by transferrin, which can bind two 
ruthenium centres. The complex is released from transferrin at acidic pH’s such as 
those found in endosomes, which is also used to release iron from transferrin inside 
the cell. Thus, it appears that KP1019 can very effectively use the natural iron 
transport systems to enter the cell. Once inside the cell, the agent can bind to DNA. 
KP1019, and its more soluble sodium salt KP1339, are undergoing clinical studies in 
humans. KP1019 has already completed a phase I clinical trial with 8 patients 
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showing 5 disease stabilizations out of the 6 patients evaluable, in some cases up to 
10 weeks even if only one cycle of drug administration was performed [197]. 
KP1019 was given as ﬂat dose to patients starting from 25 mg/patient and stopping 
dose escalation at 600 mg/patient because of solubility problems of the drug [197].  
Like NAMI-A and KP1019, (RAPTA) (Fig. 6c) agents are aryl ruthenium piano-
stool complexes [202]. RAPTA-T, similarly to almost all the other derivatives of this 
series [203] is only weakly cytotoxic, although its cytotoxicity is better against 
tumour cells than non-tumorigenic cells while showing a significant ability to 
modify cell behaviour in terms of invasion and metastasis [204]. The more recent 
RAPTA compounds [205], although conceived to mimic conventional platinum 
drugs, are generally free of in vitro cytotoxicity and have properties reminiscent of 
NAMI-A on invasion and metastasis in vitro, although in vivo they have a markedly 
different general chemistry to NAMI-A [206]. The compounds developed out of 
studies to create pH-dependent DNA-binding agents, but were shown to be of only 
very low toxicity toward cancer cell lines. Like NAMI-A, these agents are inactive 
against primary tumours but found in vivo to have activity against metastases. The 
RAPTA complexes are slightly less potent antimetastatic agents than NAMI-A, but 
(in mice) less toxic and thus can be administered in higher doses. As for NAMI-A, 
the indications are that proteins, rather than DNA, are the biomolecular targets for 
action of the drug. 
Like the gallium-based anti-cancer compound, KP46, the progress (section 1.3.1.3.1) 
of the ruthenium-based compounds are halted by a lack of information on their mode 
of action. At time of writing, NAMI-A, KP1019 and RAPTA-T are at clinical phase 
I/II, clinical phase I and preclinical evaluation respectively. For example, the strong 
and unique property to target cancer metastasis of NAMI-A should prompt the 
search for more potent and selective molecules, a process that today seems not 
possible unless we know why metastases and not the cells of the corresponding 
primary tumours are so sensitive to this drug [206]. 
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 (a) (b) (c) 
 
Figure 6: Chemical structure of ruthenium based, anti-cancer compounds NAMI-A 
(a) [194], KP1019 (b) [197] and RAPTA (c) [203].  
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1.4 Multiple Drug Resistance (MDR) 
 
Drug resistance, that is, the appearance of reduced or missing response of cancer 
cells to applied chemotherapeutic agents, is a serious problem for the treatment of 
cancer [207]. This phenomenon can be divided into intrinsic drug resistance, where 
the application of drugs has no effect at all, and acquired drug resistance, where a 
normal response is observed at the beginning of the therapy, which then diminishes 
quickly and often disappears completely after a certain period of time [208,209]. 
Multiple Drug Resistance (MDR) corresponds to a particular form of drug resistance, 
characterized by the simultaneous appearance of resistance to the applied 
chemotherapeutic agent and cross-resistance to a number of functionally and 
structurally diverse hydrophobic drugs, with different mechanisms of action 
[210.211]. 
It has been shown that MDR cells overexpress certain efflux proteins, which leads to 
a significantly lower intracellular level of chemotherapeutical agents [212]. The most 
prominent examples of this superfamily of proteins, for which a similar mechanism 
of action is assumed, are P-glycoprotein (Pgp) and MDR protein (MRP1) [213]. 
While Pgp mainly transports neutral and charged molecules in unmodified form, 
MRP1 is also able to accept metabolized substrates such as GSH, glucuronide, or 
sulfate conjugates [214-216]. 
There has been limited research on the applicability of metal-based 
chemotherapeutics to overcome MDR, however the group of Prokop et al. have 
investigated the potential of a number of metal-based compounds including yttrium 
[217], iron [218,219], titanium [220] and gold [221].  
HUNI 068 (fig. 7), an F-moc protected amino acid ferrocenyl compound [222], is 
active against cancer cells and overcomes different mechanisms of MDR, a major 
problem in the treatment of relapsed malignant diseases [223]. Tumour cells develop 
MDR by various cellular based mechanisms, for example by decreasing the pro-
/anti-apoptotic protein ratio (for example, overexpression of Bcl-2) or by excretion 
of the compound applied through membrane drug transporters, such as, p-
glycoprotein [224]. The leukemia cell line Nalm-6 was made resistant to vincristine 
(Nalm-6/Vcr) and daunorubicine (Nalm-6/Dauno). Additionally, a vincristine-
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resistant lymphoma cell line (BJAB/Vcr) was established. The Nalm-6/Vcr cells 
were tested with different common chemotherapeutic drugs, and the cells were 
tolerant to fludarabine and paclitaxel in addition, thereby fulfilling criteria of MDR 
[219].  
The multiple drug resistant Nalm-6/Vcr cells were more sensitive to treatment with 
HUNI 068 than the parental Nalm-6 cells. At 30 µM HUNI 068 induced apoptosis in 
20 % of the BJAB/Vcr population as well as the parental BJAB cells. At a higher 
concentration of 50 µM, HUNI 068 induced apoptosis in 63 % of the BJAB/Vcr 
population, while the same concentration affected 79 % of the non-resistant BJAB 
cells which suggests at a higher concentration, some mechanism of resistance may 
have an effect on apoptotic induction. 
To determine a mechanism of overcoming resistance, the expression of 84 apoptosis 
relevant genes was examined in BJAB cells treated with HUNI 068. Cells showed a 
50-fold upregulation of the pro-apoptotic harakiri gene [219]. Harakiri is an 
apoptosis-promoting protein, which interacts with Bcl-2, but not with the death-
promoting homologs, Bax or Bak [225]. It is assumed that the overexpression of 
harakiri induced by HUNI 068 neutralized the apoptosis-suppressing effects of Bcl-2 
in the BJAB/Vcr cells. 
Since the discovery of antiproliferative effects of Auranofin, an established clinical 
drug for the treatment of rheumatoid arthritis with relatively mild side effects [226], 
a huge variety of Au(I) complexes derived from Auranofin have been synthesized 
and tested for anticancer activity. Although many of these compounds showed 
promising results against a panel of cancer cell lines in vitro, their in vivo efficacy 
was limited [227]. 
A number of gold azide compounds were synthesized. Of particular interest were 
diethylphenylphosphine (4-(4-Boc-L-phenylalanine-L-leucine methyl ester)-1H,2,3-
triazolyl)gold(I) 6b and diethylphenylphosphine (4-(4-L-phenylalanine-D-arginine-
L-phenylalanine-L-lysine-amide)-1H,2,3-triazolyl)gold(I) 8b and the effect of the 
gold-peptide conjugates on p53-mutant MDA-MB231 breast cancer cells was 
evaluated. Besides high aggressiveness and poor prognosis, mutant-p53 expressing 
tumours also display increased resistance against various anticancer treatments 
[228]. 
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A Bionas sensor chip system was employed, which is used for the continuous online 
measurement of essential cellular parameters, such as respiration rate and 
extracellular acidification rate [229, 230]. The respiration rate is a direct measure of 
ATP production within functional mitochondria, while the acidification rate mainly 
indicates the presence of lactic acid, a product from the anaerobic oxidation of 
NADH to NAD+ during glycolysis. Alterations in both of these cellular functions 
play a role in apoptosis. 
As expected, incubation of p53-mutant MDA-MB-231 cells with 20 µM cisplatin did 
not significantly alter the respiration and acidification rate compared to the non-
treated control. In contrast, exposure to 20 µM 6b and 8b strongly affects both 
cellular parameters. The standard respiration rate drops to 20 % within just 3–7 hours 
after the addition of 6b, 8b. The strong decrease in cellular respiration is mirrored by 
an initially steep increase of the standard acidification rate for 6b and 8b which can 
be explained by an enhanced compensatory glycolysis. Ultimately, as the cells 
perish, all parameters irreversibly drop to basal levels. The results show that the 
(phosphine)gold(I) conjugates are able to break the resistance of the p53-mutant 
MDA-MB231 cells against cisplatin, which also points to a different mode of action 
for these gold drugs compared to the former. It has been shown that unlike cisplatin, 
DNA can be excluded as a relevant target for these gold peptide conjugates [231]. 
Instead it has been proposed that inhibition of thioredoxin reductase (TrxR), an 
important enzyme within the cellular and mitochondrial redox system, is the most 
relevant factor for the antiproliferative effects displayed by gold compounds [232]. 
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Figure 7: Chemical structure of HUNI 
068 [222] 
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1.5 Drug Solubility 
 
Organometallic complexes are not normally soluble in aqueous media, however in 
vitro experiments can be carried out in the presence of a low percentage of alcohol or 
DMSO (0.5-1 %) without causing any damage to cells. To conduct in vivo 
evaluations, it is necessary to address the water solubility issue of these lipophilic 
molecules. DMSO is one of the most common solvents used experimentally to 
dissolve hydrophobic substances for in vivo and in vitro purposes. The toxicity of 
DMSO is low: LD50 in mice is 6.2 mL/kg (when applied intraperitoneally (i.p)) or 
3.7 mL/kg (applied intravenously (i.v.)), LD50 in rats is 9.9 mL/kg (i.p) or 7.4 mL/kg 
(i.v.) [233]. However, DMSO by itself has a variety of biological actions which can 
confound the effects of drugs when DMSO is used as a vehicle. A substantial effect 
has been found even with doses as low as 0.1 mL/kg [234]. For this reason it is 
favourable to find alternative vehicles for drug delivery in vivo. 
Following the discovery of the strong antiproliferative effects of the ferrocifens in 
vitro, in vivo studies were performed. These experiments were carried out in nude 
mice on xenografts of different cancers (breast, ovarian, prostate). In these first tests 
Fc-OH-Tam and Fc-diOH, were solubilized in a mixture of PEG300 and 
carboxymethylcellulose and administered by intraperitoneal injection or orally. None 
of these experiments led to significant regression of the tumours in the treated mice 
and very rapid elimination of the complexes from the circulatory system was noted. 
The solution was found in the newly available option of working with lipid 
nanocapsules, which provided some very interesting approaches for the formulation 
of this family of molecules. The effect of Fc-diOH was tested in rats, implanted with 
brain tumours (9L glioma cells). This cell line is classically used as a model for 
human glioblastoma, a particularly aggressive cancer that remains incurable to date. 
The injection of Lipid Nanocapsules (LNC) containing Fc-diOH induced a 
significant reduction in the growth of the tumours by approximately 75-80 %. The 
use of this formulation allowed, for the first time, observation of an in vivo effect on 
tumour growth [235]. 
After this a new generation of LNCs were developed. A PEG moiety with a long 
chain (DSPE-mPEG2000) is added to the surface of the first-generation LNC to 
produce a stealth effect, that is, to make the LNC undetectable by the animal’s 
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immune system and thus increase the time they remain in the animal’s circulatory 
system. This time the LNC were administered intravenously and the results obtained 
were spectacular, since in this case an almost-total disappearance of the tumours was 
observed in the treated animals after 21 days [236]. 
Nanomedicines have appeared as a compelling system to develop an injectable 
formulation of Fc-O-HTAM offering great benefits such as increased bioavailability, 
protection against in vivo degradation and enhancement of pharmacokinetic 
properties [237]. 
The method used to load the LNCs with Fc-OH-TAM is a 2 step process. Step one 
involves mixing all the excipients (Solutol® HS15 (17.2 % w/w), Lipoid® (1.5 % 
w/w), Labrafac® (20.8 % w/w), NaCl (0.5 % w/w) and water (60 % w/w) under 
magnetic stirring and heating from room temperature to 90 °C. Three cycles of 
progressive cooling and heating between 90 and 60 °C were then carried out. Step 
two is an irreversible shock induced by sudden dilution with water (28.5 % (v/v)) 
applied to the mixture at 70-72 °C. Slow magnetic stirring was then applied to the 
suspension for 5 minutes. Fc-OH-TAM loaded LNCs were prepared according to 
this process with drug added as a solid powder at step one to the other excipients. 
The drug was solubilized during the heating step and ultimately encapsulated over 
the last cooling step [238]. 
This method allowed successful delivery of Fc-OH-TAM to mice bearing TNBC 
(Triple Negative Breast Cancer) xenografted tumours in severe combined 
immunodeficiency (SCID) mice. Fc-OH-TAM-LNC treatment markedly delayed the 
tumour growth compared to the untreated control group and the unloaded LNC 
treated group, which had similar tumor evolutions. As a result, the hampered tumour 
growth rate led to an impressive low tumour volume at day 38 with 36 % tumour 
volume reduction compared to that of control groups [239]. 
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2.1. Cells and Reagents 
 
Growth Media and Foetal Calf Serum (FCS) were obtained from Sigma-Aldrich. 
Cell lines were maintained at 37 °C with 5 % CO2. 
 
Table 2.1: Details of cell lines and growth conditions used for this study. 
Cell Name Source Cell Type Media + Additives 
HT144 ATCC Melanoma RPMI + 10 % FCS 
Lox-IMVI NCI Melanoma RPMI + 10 % FCS 
Malme-3M NCI Melanoma RPMI + 10 % FCS 
Malme-3M-
TMZ 
NICB 
Cell 
Bank 
Temozolomide Resistant 
Melanoma 
RPMI + 10 % FCS 
Sk-Mel-28 NCI Melanoma RPMI + 10 % FCS 
A549 ATCC Adenocarcinoma 
DMEM/Ham’s F12 + 10 
% FCS 
A549-Cpt 
NICB 
Cell 
Bank 
Carboplatin resistant 
Adenocarcinoma 
DMEM/Ham’s F12 + 10 
% FCS 
H1299 ATCC 
Non-small Cell Lung 
Carcinoma 
RPMI + 10 % FCS +         
10 mM L-Glutamine 
SKBR3 ATCC Breast Cancer RPMI + 10 % FCS 
MDA-MB-
361 
ATCC Breast Cancer RPMI + 10 % FCS 
NHDF Clonetics 
Normal human dermal 
fibroblast 
DMEM + 10 % FCS 
 
2.2 Compound Preparation 
 
All ferrocene-based compounds were synthesised by Dr Peter Kenny’s research 
group, School of Chemical Sciences, Dublin City University. Compounds were 
weighed using an analytical balance and dissolved in DMSO (Sigma) to a 
concentration of 10 mM. 1 mL was aliquoted and was used as a working stock. The 
remainder was stored at -20 °C. The synthesis of tested compounds is described in 
Section 1.3.2.2. 
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2.3. Proliferation Assays 
 
Proliferation was measured using an acid phosphatase assay. 1 x 10
3
 cells/well were 
seeded in 96-well plates, except for HT144 and Malme-3M which were seeded at 2 x 
10
3
 cells/well. Plates were incubated overnight at 37 °C followed by addition of drug 
at the appropriate concentrations and incubated for a further 5 days until wells were 
80 % to 90 % confluent. All media was removed and the wells were washed once 
with PBS (Sigma). 10 mM paranitrophenol phosphate substrate (Sigma-Aldrich) in 
0.1 M sodium acetate buffer (Sigma) with 0.1 % Triton X (Sigma) pH 5.5 was added 
to each well and incubated at 37 °C for 2 hours. 50 μL of 1 M NaOH (Sigma) was 
added and the absorbance was read at 405 nM (reference – 620 nM). 
 
2.3.1 Screening of Compounds 
 
Due to the large volume of compounds which were to be tested, the amount of 
compound to be evaluated was reduced by conducting preliminary screenings. This 
involved treating the cell with 10 µM of each compound and depending on the 
percentage growth inhibition, compounds were selected for IC50 analysis. 
Compounds which showed very high levels of anti proliferative activity were further 
screened at 1 µM 
 
2.4. Mycoplasma analysis of cell lines 
 
Cell lines were tested for possible Mycoplasma contamination every three months 
approximately. Mycoplasma negative NRK (normal rat kidney fibroblast) cells were 
used as indicator cells for this analysis. The cells were incubated with a sample 
volume of supernatant from the cell lines in question and then examined for 
Mycoplasma contamination. A fluorescent Hoechst stain (Sigma) was used in this 
analysis. The stain binds specifically to DNA and stains the nucleus of the cell in 
addition to any Mycoplasma present. Mycoplasma infection was indicated by 
fluorescent bodies in the cytoplasm of the NRK cells. 
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2.5. Cell Cycle Analysis 
 
The Guava Cell Cycle Assay uses the nuclear DNA stain, propidium iodide (PI), to 
measure cell cycle. Resting cells (G0/G1) contain two copies of each chromosome. 
Cells undergoing mitosis synthesize chromosomal DNA (S phase), which results in 
increased fluorescence intensity. When all chromosomal DNA has doubled (G2/M 
phase), cells fluoresce with twice the intensity of the initial population. 2.5 x 10
4
 
cells were seeded per well in 24-well plates and incubated overnight at 37 °C. After 
24 hours appropriate concentrations of test compound were added to the wells. Plates 
were then incubated at 37 °C for a further 72 hours. Media was collected and the 
wells washed once with PBS (Sigma). Cells were trypsinised and added to the media 
collected for each sample. Cells were centrifuged at 300 x g for 5 minutes and the 
media was aspirated. The cell pellet was re-suspended in 150 μL PBS and transferred 
to a round bottomed 96 well plate. The plate was centrifuged at 300 x g for 5 minutes 
and the supernatant aspirated leaving approximately 15 μL in each well. The 
remaining volume was used to resuspend the cells and 200 μL of ice cold 70 % 
ethanol (Fluka) was added. The plates were then stored at -20 °C for 2 hours. After 
fixing, the cells were centrifuged at 450 x g for 5 minutes, the supernatant removed, 
washed with 200 μL of PBS and centrifuged again at 450 x g. The PBS was then 
removed and 200 μL of Guava Cell Cycle reagent (Millipore) was added to each 
well. The cells were mixed by pipetting and stored at room temperature shielded 
from light for 30 minutes. Cells were analysed on the Guava EasyCyte (Guava 
Technologies). 
 
2.6. Apoptosis Assay using Terminal DNA Transferase-mediated dUTP Nick 
End Labelling (TUNEL). 
 
The Guava
®
 TUNEL Assay detects apoptosis-induced DNA fragmentation through a 
quantitative fluorescence assay. Terminal deoxynucleotidyl transferase (TdT) 
catalyzes the incorporation of bromo-deoxyuridine (BrdU) residues into the 
fragmenting nuclear DNA at the 3'-hydroxyl ends by nicked end labelling. A TRITC 
conjugated anti-BrdU antibody can then label the 3'-hydroxyl ends for detection by a 
Guava System. 2.0 x 10
4
 cells were seeded per well in 24-well plates and incubated 
overnight at 37 °C, followed by addition of test compound at the appropriate 
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concentrations. After 72 hours, media was removed and the wells washed once with 
PBS (Sigma). Cells were trypsinised and resuspended in 1 mL of media before being 
transferred to an eppendorf. Cells were centrifuged at 300 x g for 5 minutes and the 
medium was aspirated. The pellet was re-suspended in 150 μL of PBS and 
transferred to a round bottomed 96 well plate. 50 μL of 4 % para-formaldehyde 
(Sigma) prepared in PBS was added to the wells and mixed. Cells were incubated at 
4 °C for 60 minutes. The plate was centrifuged at 300 x g for 5 minutes and the 
supernatant aspirated leaving approximately 15 μL in each well. The remaining 
volume was used to resuspend the cells and 200 μL of ice cold 70 % ethanol (Fluka) 
was added to the cells. The plates were then stored at -20 °C for at least 2 hours 
(maximum 2 weeks). After fixation, the cells including positive and negative 
controls (Millipore) were centrifuged at 300 x g for 5 minutes. The supernatant was 
aspirated, and the cells washed with 200 μL of wash buffer (Millipore) and then 
centrifuged again at 300 x g for 5 minutes. The wash buffer was aspirated and 25 μL 
of DNA labelling mix (Millipore) was added to each well and the cells mixed. The 
plates were covered with parafilm and incubated for 60 minutes at 37 °C. 200 μL of 
rinsing buffer (Millipore) was then added to each well and the plates centrifuged at 
300 x g for 5 minutes. The supernatant was aspirated and 50 μL of anti-BrdU 
staining mix (Millipore) added to each well, with the plate stored in the dark at room 
temperature for 30 minutes. At the end of the incubation 150 μL of rinsing buffer 
was added to each well. Cells were analysed on the Guava EasyCyte (Guava 
Technologies). Positive and negative controls were performed with each assay. 
 
2.7. Drug Solubility 
 
DMSO (Sigma) was used to prepare stock solutions of ferrocene-based compounds 
and was suitable for use in vitro as the low levels needed do not have a significant 
effect on cells used. 
A number of vehicles were used in an attempt to solubilise N-{6-ferrocenyl-2-
naphthoyl}-glycine-glycine ethyl ester to a concentration of 2 mg/mL. The vehicles 
used are listed below (table 2.2). 
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Table 2.2: List of vehicles used as an alternative to DMSO as a vehicle for 
compound delivery in vivo. 
Vehicle Source 
80 mM citrate buffer Sigma 
5 % Carboxymethyl Cellulose  Sigma 
1 % Carboxymethyl Cellulose Sigma 
50 % Propylene Glycol solution Sigma 
Intralipid® 20 % Fresenius Kabi 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl ester was insoluble in the 
vehicles alone, as it was first dissolved in DMSO at a concentration of 8 mg/mL and 
then diluted 1 in 4 with 80 mM citrate buffer/5 % Carboxymethyl Cellulose/1 % 
Carboxymethyl Cellulose/50 % Propylene Glycol solution to give a 2 mg/mL 
solution. 
Intralipid, which is used in some preparations of the anaesthetic drug, propfol, was 
tested. N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl ester compound was 
initially dissolved in chloroform at a concentration of 2 mg/mL. Once in solution, it 
was transferred to a round-bottom flask followed by evaporation using a rotary 
vacuum apparatus (Buchi Rotavapor R-210 with a B-491 heating bath, V-700 
vacuum pump) until the chloroform (Sigma) had fully evaporated and a thin layer of 
the compound was left on the inside wall of the flask. Intralipid was then added to 
resolubilise the compound at 2 mg/mL however the compound did not solubilise.   
A PEGylated derivative of N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl ester 
(61) was synthesized and dissolved in ultrapure water (UHP). This water was 
purified to a standard of 12-18 MΩ / cm resistance by a reverse osmosis system 
(Millipore Milli-RO 10 Plus, Elgastat UHP). The solution was then filter sterilised 
through a 0.22 µm sterile filters (Millipore). 
 
2.8 Statistical Analysis 
 
IC50 values were calculated using CalcuSyn Software (BioSoft). Student t-test (two-
tailed with unequal variance) was used to compare the activity of test compounds to 
their corresponding control group. 
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3.1. Cytotoxicological evaluation of 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters 
 
3.1.1 Introduction  
 
Organometallic compounds containing transition metals, such as cobalt, copper, iron 
and platinum are known to have antiproliferative (in vitro) and antineoplastic (in 
vivo) activities. Platinum coordination compounds, such as cisplatin and carboplatin 
are currently being used in the treatment of a variety of tumours [240]. However, 
problems with toxicity, harsh side effects during administration and acquired drug 
resistance have lead to increased research to find alternatives to cisplatin and its 
analogues.  
Ferrocene is a particularly useful organometallic compound for biological 
applications due to its electrochemical properties, its stability and its aromatic nature 
which allows for derivatization. As a result of these factors, ferrocene research has 
received an increased level of interest over the past decade
 
[240]. Ferricenium salts 
are known to inhibit tumour growth through the formation of hydroxyl radicals 
under physiological conditions, leading to the oxidative damage of DNA [241].
 
 The 
aim of this research is to develop novel ferrocenyl dipeptide bioconjugates for use as 
potential anticancer agents and to elucidate potential modes of action which cause 
their antiproliferative activity. 
Previous studies within the group have been carried out on the non small cell lung 
cancer (NSCLC) cell line, H1299 to evaluate the in vitro activity of novel ferrocenyl 
benzoyl amino acid and dipeptide esters. The effect of these compounds on H1299 
cell growth was expressed as IC50 values. The IC50 value is the concentration of a 
drug required for 50 % inhibition of cell growth.  N-{ortho-(ferrocenyl) benzoyl} 
glycine ethyl ester was initially tested for its in vitro anti-proliferative activity 
against H1299 lung cancer cells.  This compound was found to be cytotoxic and had 
an IC50 value of 48 ± 1.0 µM, whereas the starting material, ortho-ferrocenyl ethyl 
benzoate, was completely inactive against the cell line. Therefore, other derivatives 
were prepared and evaluated for their anticancer activity against H1299 lung cancer 
cells. The dipeptide derivative N-{ortho-(ferrocenyl) benzoyl} glycine glycine ethyl 
ester was shown to have an IC50 value of approximately 20 ± 1.7 µM, while N-
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{ortho-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester had an IC50 value of 5.3 ± 
1.2 µM. The N-{meta-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester and N-
{para-(ferrocenyl)-benzoyl} glycine L-alanine ethyl ester were also tested and gave 
results of 4.0 ± 0.7 µM and 6.6 ± 1.0 µM respectively [126-130].  
As an extension of this study the cytotoxicological evaluation is reported of novel 1-
alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters 
synthesised by Dr Peter Kenny’s research group, School of Chemical Sciences, 
Dublin City University. These compounds (Figure 3.1) consist of four key moieties:  
(i) A redox active centre 
(ii) A conjugate linker  
(iii) A alkyl chain (further lowers the oxidation potential of the ferrocene 
moiety) 
(iv) A dipeptide chain 
These novel derivatives differ from the N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters by having an alkyl moiety on the previously unsubstituted 
cyclopentadiene ring (Figure 3.1). The primary objective of this research is to 
explore a structure-activity relationship (SAR) study of the incorporation of alkyl 
chains moieties on the unsubstituted ring of the N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters [126-130]. The dipeptides employed in this 
investigation were Glycine Glycine (Gly Gly), Glycine L-Alanine (Gly L-Ala), 
Glycine L-Leucine (Gly L-Leu) and Glycine L-Phenylalanine (Gly L-Phe) ethyl 
esters. A tripeptide or tetrapeptide chain was shown to have a negative effect on 
biological activity [129].
 
Thus, a series of novel 1-alkyl-1’-N-para, N-meta and N-
ortho-(ferrocenyl) benzoyl dipeptide esters 64–99 were prepared by coupling alkyl 
ferrocenyl benzoic acids to the dipeptide ethyl esters (Table 3.1). 
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64–99 
R = CH3 , CH2CH3 , CH2CH2CH3 
R’ = H, CH3 , C4H9, C7H7, 
Figure 3.1: General structure of the 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters 64–99. 
 
 
(i) NaNO2, HCl 
(ii) EDC, HOBt, Triethylamine and dipeptides ethyl esters (R3) 
Figure 3.2: The synthesis of 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters 64–99. 
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Table 3.1: The 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters 64–99 evaluated in this study. 
R
1
 R
2
 R
3
 Compound no. 
 
-CH3 
(1-methyl-1’) 
 
N-para 
Gly Gly(OEt) 64 
Gly L-Ala(OEt) 65 
Gly L-Leu(OEt) 66 
Gly L-Phe(OEt) 67 
 
N-meta 
Gly Gly(OEt) 68 
Gly L-Ala(OEt) 69 
Gly L-Leu(OEt) 70 
Gly L-Phe(OEt) 71 
 
N-ortho 
Gly Gly(OEt) 72 
Gly L-Ala(OEt) 73 
Gly L-Leu(OEt) 74 
Gly L-Phe(OEt) 75 
 
-CH2CH3 
(1-ethyl-1’) 
 
N-para 
Gly Gly(OEt) 76 
Gly L-Ala(OEt) 77 
Gly L-Leu(OEt) 78 
Gly L-Phe(OEt) 79 
 
N-meta 
Gly Gly(OEt) 80 
Gly L-Ala(OEt) 81 
Gly L-Leu(OEt) 82 
Gly L-Phe(OEt) 83 
 
N-ortho 
Gly Gly(OEt) 84 
Gly L-Ala(OEt) 85 
Gly L-Leu(OEt) 86 
Gly L-Phe(OEt) 87 
 
-CH2CH2CH3 
(1-propyl-1’) 
 
N-para 
Gly Gly(OEt) 88 
Gly L-Ala(OEt) 89 
Gly L-Leu(OEt) 90 
Gly L-Phe(OEt) 91 
 
N-meta 
Gly Gly(OEt) 92 
Gly L-Ala(OEt) 93 
Gly L-Leu(OEt) 94 
Gly L-Phe(OEt) 95 
 
N-ortho 
Gly Gly(OEt) 96 
Gly L-Ala(OEt) 97 
Gly L-Leu(OEt) 98 
Gly L-Phe(OEt) 99 
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3.1.2 Cytotoxicological evaluation of 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters 
 
In previous studies carried out to evaluate the in vitro anticancer activity of N-para, 
N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters (figure 3.3) in non small 
cell lung cancer cell line, H1299, the general trend in cytotoxicity was para < ortho 
< meta. The dipeptide derivative N-{ortho-(ferrocenyl) benzoyl} glycine L-alanine 
ethyl ester was shown to have an IC50 value of 5.3 ± 1.2 µM. The N-{para-
(ferrocenyl) benzoyl} glycine L-alanine ethyl ester and the N-{meta-(ferrocenyl) 
benzoyl} glycine L-alanine ethyl ester had IC50 values of 6.6 ± 1.0 µM and 4.0 ± 0.7 
µM respectively [126-130].   
In a further SAR study a series of 1-alkyl-1’-N-para, N-meta and N-ortho-
(ferrocenyl) benzoyl dipeptide esters were synthesised, structurally characterised and 
biologically evaluated. In total, 36 compounds were tested for their anti-proliferative 
effect on the non small cell lung cancer cell line, H1299. These novel derivatives 
differ from the N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters by 
having an alkyl moiety on the previously unsubstituted ferrocene ring. 
 
 
alkyl moiety (R) = CH3;  CH2CH3; CH2CH2CH3 
R’ = H; CH3; C4H9; C7H7 
Figure 3.3: General structure of the N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters and the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters.  
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3.1.3. In vitro cytotoxicity of 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters   
 
The in vitro cytotoxicity of the 1-alkyl-1’ derivatives 64–99 was evaluated by 
performing a comprehensive screen of every compound at a single dose (10 μM) in 
the H1299 cell line. The comprehensive screen was performed in triplicate by 
treating individual wells of a 96-well plate containing H1299 cells with a 10 μM 
solution of each test compound prepared in DMSO. A DMSO control and a control 
for normal (untreated) cell growth were included in the assays. The cells were then 
incubated for 5 days, until cell confluency was reached. At this point, cell survival 
was established through determination of the acid phosphatase activity of surviving 
cells. The results of the comprehensive screens are expressed as the percentage 
growth inhibition ± standard deviation (relative to the DMSO controls). Standard 
deviations have been calculated using data obtained from three independent 
experiments. The results for the preliminary screen of compounds 64–99 are 
depicted in figures 3.4-3.6.  
 
 
Figure 3.4: Percentage growth of H1299 cells after treatment of 10 µM of 
compounds 64-75. Growth is expressed relative to cells treated with an equivalent 
volume of DMSO. Error bars represent the standard deviation of triplicate 
experiments 
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Table 3.2: Percentage growth of H1299 lung cancer cells treated with 10 µM 1-
methyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters 64–75.  
Alkyl Benzoyl
 
Dipeptide ethyl  
ester 
Compound 
No. 
% growth at 
10 µM 
 
-CH3 
(1-methyl-1’) 
 
N-para 
Gly Gly(OEt) 64         17 ± 4.3 
Gly L-Ala(OEt) 65 17 ± 1.0 
Gly L-Leu(OEt) 66 72 ± 2.9 
Gly L-Phe(OEt) 67 80 ± 2.8 
 
N-meta 
Gly Gly(OEt) 68 16 ± 3.8 
Gly L-Ala(OEt) 69 16 ± 1.3 
Gly L-Leu(OEt) 70 59 ± 1.0 
Gly L-Phe(OEt) 71 80 ± 2.9 
 
N-ortho 
Gly Gly(OEt) 72 62 ± 2.4 
Gly L-Ala(OEt) 73 52 ± 1.5 
Gly L-Leu(OEt) 74 72 ± 2.6 
Gly L-Phe(OEt) 75 80 ± 3.7 
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Figure 3.5: Percentage growth of H1299 cells after treatment of 10 µM of 
compounds 76-87. Growth is expressed relative to cells treated with an equivalent 
volume of DMSO. Error bars represent the standard deviation of triplicate 
experiments. 
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Table 3.3: Percentage growth of H1299 cells after treatment of 10 µM of 
compounds 76-87. 
Alkyl Benzoyl
 Dipeptide 
ethyl ester 
Compound 
No. 
% growth at 
10 µM 
 
-CH2CH3 
(1-ethyl-1’) 
 
N-para 
Gly Gly(OEt) 76 17 ± 1.5 
Gly L-
Ala(OEt) 
77 16 ± 2.3 
Gly L-
Leu(OEt) 
78 66 ± 1.5 
Gly L-
Phe(OEt) 
79 81 ± 3.6 
 
N-meta 
Gly Gly(OEt) 80 30 ± 2.6 
Gly L-
Ala(OEt) 
81 27 ± 1.7 
Gly L-
Leu(OEt) 
82 57 ± 0.8 
Gly L-
Phe(OEt) 
83 70 ± 2.4 
 
N-ortho 
Gly Gly(OEt) 84 66 ± 1.9 
Gly L-
Ala(OEt) 
85 54 ± 1.8 
Gly L-
Leu(OEt) 
86 80 ± 2.5 
Gly L-
Phe(OEt) 
87 83 ± 1.3 
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Figure 3.6: Percentage growth of H1299 cells after treatment of 10 µM of 
compounds 88-99. Growth is expressed relative to cells treated with an equivalent 
volume of DMSO. Error bars represent the standard deviation of triplicate 
experiments. 
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Table 3.4: Percentage growth of H1299 cells after treatment of 10 µM of 
compounds 88-99. 
Alkyl Benzoyl
 Dipeptide ethyl 
ester 
Compound 
No. 
% growth at 
10 µM 
-
CH2CH2CH3 
(1-propyl-1’) 
 
N-para 
Gly Gly(OEt) 88 24 ± 3.4 
Gly L-Ala(OEt) 89 20 ± 4.5 
Gly L-Leu(OEt) 90 45 ± 1.9 
Gly L-Phe(OEt) 91 66 ± 2.5 
 
N-meta 
Gly Gly(OEt) 92 24 ± 3.1 
Gly L-Ala(OEt) 93 20 ± 4.1 
Gly L-Leu(OEt) 94 45 ± 0.9 
Gly L-Phe(OEt) 95 72 ± 2.3 
 
N-ortho 
Gly Gly(OEt) 96 68 ± 1.6 
Gly L-Ala(OEt) 97 62 ± 0.6 
Gly L-Leu(OEt) 98 80 ± 2.6 
Gly L-Phe(OEt) 99 86 ± 3.4 
From the preliminary screen at 10 μM a general trend can be observed, the 1-alkyl-
1’- N-ortho- derivatives exhibited lower growth inhibition compared to the meta and 
para derivatives for the dipeptides employed in the SAR study. For instance, the 1-
methyl-1’-N-{ortho-(ferrocenyl) benzoyl} glycine glycine ethyl ester 72 inhibited 
growth by 38 ± 2.4 % whilst the 1-methyl-1’-N-para and meta-(ferrocenyl) benzoyl} 
glycine glycine ethyl ester (64 and 68) inhibited growth by 83 ± 4.3 % and 84 ± 3.8 
% respectively. The ortho derivatives were not investigated further.  
A general trend was also observed in these compounds, that is, the Gly Gly (OEt) 
and Gly L-Ala (OEt) derivatives are more active than the Gly L-Leu and Gly L-Phe 
ethyl esters which inhibit growth by greater than 45 %. For instance the 1-ethyl-1’-
N-{para-(ferrocenyl) benzoyl} glycine glycine ethyl ester 76 and glycine L-alanine 
ethyl ester 77 inhibit growth by 83 ± 1.5 % and 84 ± 2.3 % respectively, whilst the 
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Gly L-Leu(OEt) 78 and Gly L-Phe(OEt) 79 inhibited growth by 34 ± 1.6 % and 19 ± 
3.6 respectively. Thus, the Gly L-Leu and Gly L-Phe ethyl ester derivatives were not 
investigated further. As a result, it can be concluded that when chiral α-amino acids 
with bulky side chains are used as the second amino acid in the dipeptide moiety a 
loss of anti-proliferative activity is observed for this particular group of compounds. 
For the 1-alkyl-1’-N-para, N-meta-(ferrocenyl) benzoyl dipeptide esters, 12 lead 
compounds were identified which inhibited growth greater than 70 % and therefore, 
IC50 values were determined for these compounds. 
 
Table 3.5. IC50 values for selected compounds, carboplatin and cisplatin against 
human lung carcinoma cell line H1299. 
Compound Name                                                                             No.       IC50(µM) 
Cisplatin 8 1.5 ± 0.1 
Carboplatin 9 10.0 ± 1.6 
 
1-methyl-1’ -N- {para-(ferrocenyl)-benzoyl} Gly Gly(OEt) 
 
64 2.8 ± 1.2 
1-methyl-1’ -N- {para-(ferrocenyl)-benzoyl} Gly L-Ala(OEt) 
 
65 4.5 ± 0.4 
1-methyl-1’ -N- {meta-(ferrocenyl)-benzoyl} Gly Gly(OEt) 
 
68 2.6 ± 0.6 
1-methyl-1’ -N- {meta-(ferrocenyl)-benzoyl} Gly L-Ala(OEt) 
 
69 6.7 ± 0.3 
 
1-ethyl-1’ -N- {para-(ferrocenyl)-benzoyl} Gly Gly(OEt) 
 
76 3.5 ± 0.8 
1-ethyl-1’ -N- {para-(ferrocenyl)-benzoyl} Gly L-Ala(OEt) 
 
77 5.6 ± 1.6 
1-ethyl-1’ -N- {meta-(ferrocenyl)-benzoyl} Gly Gly(OEt) 
 
80 6.1 ± 1.1 
1-ethyl-1’ -N- {meta-(ferrocenyl)-benzoyl} Gly L-Ala(OEt) 
 
81 13.3 ± 1.1 
 
1-propyl-1’ -N- {para-(ferrocenyl)-benzoyl} Gly Gly(OEt) 
 
 
88 
 
5.4 ± 1.2 
1-propyl-1’ -N- {para-(ferrocenyl)-benzoyl}Gly L-Ala(OEt) 
 
89 6.6 ± 2.1 
1-propyl-1’ -N- {meta-(ferrocenyl)-benzoyl} Gly Gly(OEt) 
 
92 11.3 ± 2.1 
1-propyl-1’ -N- {meta-(ferrocenyl)-benzoyl} Gly L-Ala(OEt) 
 
93 20.1 ± 2.5 
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From the IC50 values (Table 3.5) of the 1-alkyl-1’-N-para, N-meta -(ferrocenyl) 
benzoyl Gly Gly and Gly L-Ala ethyl esters 64, 65, 68, 69, 76, 77, 80, 81, 88, 89, 92 
and 93, it can be seen that the cytotoxicity of the derivatives decreases as the size of 
the alkyl moiety incorporated increases (methyl < ethyl < propyl). Indeed, all the 
methyl and ethyl derivatives display IC50 values that are lower than 15 µM. The in 
vitro cytotoxicity of the platinum (II) based anticancer drug carboplatin was also 
evaluated against the H1299 cell line and the carboplatin IC50 value was determined 
to be 10.0 ± 1.6 µM (Table 3.5). Thus, compounds 64, 65, 68, 69, 76, 77, 80, 88 and 
89 are more cytotoxic in vitro than the clinically employed anticancer drug 
carboplatin. In addition, the 1-methyl-1’-N-{para-(ferrocenyl) benzoyl} glycine 
glycine ethyl ester 64 displays an IC50 value of 2.8 ± 1.2 µM,  the 1-ethyl-1’–N-
{para-(ferrocenyl) benzoyl} glycine glycine ethyl  ester 76 displays an IC50 value of 
3.5 ± 0.8 µM and the 1-methyl- 1’ -N- {meta-(ferrocenyl)-benzoyl} glycine glycine 
ethyl ester 68 shows an IC50 value of 2.6 ± 0.6 µM. These compounds display 
improved bioactivity in comparison to the most active ferrocenyl benzoyl analogues 
previously studied. The N-{meta-(ferrocenyl) benzoyl} glycine L-alanine ethyl ester 
displayed an IC50 value of 4.0 ± 0.7 µM.
 
[129] 
From these results, incorporation of methyl and ethyl alkyl groups results in an 
improved cytotoxicity of the para derivatives of the glycine glycine ethyl esters and 
an improved cytotoxicity of the methyl meta glycine glycine derivative. However, 
when the size of the chain length increased to ethyl, the 1-ethyl-1’-N-{meta-
(ferrocenyl)-benzoyl} glycine L-alanine ethyl ester 81 displayed an IC50 of 13.3 ± 
1.1 µM. Thus, the increase in alkyl chain length resulted in a drastic decrease in the 
cytotoxicity of the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters. Although compounds 64 and 68 are the most active derivatives of 
the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters, 
they are less potent than cisplatin which has an IC50 value of 1.5 ± 0.1 µM against 
human H1299 lung cancer cells. 
 
3.1.4 Conclusion 
 
Cytotoxicity of the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl 
dipeptide esters, decreases with the increase of the size of the alkyl group 
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incorporated (propyl < ethyl < methyl) on the ferrocene moiety. All the methyl and 
ethyl derivatives have IC50 values that are lower than 15 µM. The order of the amino 
acids in the dipeptide chain is crucial for activity, the trend being Gly Gly > Gly L-
Ala > Gly L-Leu > Gly L-Phe. The most active derivatives of the 1-alkyl-1’-N-para, 
N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters are the 1-methyl-1’-N-
{para-(ferrocenyl) benzoyl} glycine glycine ethyl ester 64 and the 1-methyl-1’-N-
{meta-(ferrocenyl) benzoyl} glycine glycine ethyl ester 68 which display IC50 values 
of 2.8 ± 1.23 µM and 2.6 ± 0.62  µM respectively. These compounds are more active 
than carboplatin but are less effective compared to cisplatin which are clinically 
employed anticancer drugs. 
 
3.2. Cytotoxicological evaluation of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-
(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} 
amino acid and dipeptide esters 
 
3.2.1. Introduction 
 
To date we have shown that the replacement of the conjugated linker of N-
(ferrocenyl) benzoyl dipeptide esters with a naphthoyl linker leads to an 
improvement in antiproliferative effect in the non small cell lung cancer (NSCLC) 
cell line, H1299 [132-134].
 
From the series of N-(ferrocenyl) naphthoyl amino acid 
and dipeptide ethyl esters reported, the N-{6-(ferrocenyl)-2-napthoyl} glycine 
glycine ethyl ester 31 displayed an IC50 value of 0.13 ± 0.01 µM in the H1299 lung 
cancer cell  line [134]. 
We have been clearly demonstrated in the SAR study of the 1-alkyl-1’ derivatives 
that employing the incorporation of a methyl derivative to the unsubstituted 
cyclopentadiene ring enhances the anti-proliferative effect of the ferrocenyl 
dipeptide bioconjugates. The most active derivative was the 1-methyl-1’-N-{meta-
(ferrocenyl) benzoyl} glycine glycine ethyl ester 68 which displayed an IC50 value of 
2.6 ± 0.6 µM.  
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In a continuation to this SAR study in search for novel compounds with increased 
anti-proliferative effect, a new library of ferrocenyl based bioconjugates 105-138, 
which consist of four key moieties was synthesised (figure 3.8): 
(i) An electroactive core  
(ii) An ethynyl moiety  
(iii) Three different aromatic linkers  
(iv)  A series of amino acid and dipeptide esters  
This SAR study involves the cytotoxicological evaluation of the incorporation of an 
ethynyl moiety between the ferrocene moiety and the conjugate linker. Furthermore, 
the incorporation of L-leucine and L-phenylalanine into the dipeptide chains have 
been shown in the preliminary screen of the 1-alkyl-1’ derivatives (64-69)  to 
display low activity against the H1299 lung cancer cell line. The dipeptides and the 
amino acid employed were Glycine Glycine (Gly Gly), Glycine L-Alanine (Gly L-
Ala), Glycine D-Alanine (Gly D-Ala), Sarcosine Glycine (Sar Gly), Sarcosine L-
Alanine (Sar L-Ala), L-Proline L-Alanine (L-Pro L-Ala), L-Proline Glycine (L-Pro 
Gly), Glycine L-Leucine (Gly L-Leu) and Glycine L-Phenylalanine (Gly L-Phe) and 
γ-aminobutyric acid (GABA). 
Figure 3.7: General structure of the N-(ferrocenyl) benzoyl and naphthoyl 
bioconjugates and N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino acid and 
dipeptide esters. 
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(i) TEA, PPh3, Bis(triphenylphosphine)palladium(II) dichloride, THF, Cu(I) 
(ii) EDC, HOBt, triethylamine, dipeptide esters and free N-terminal γ-Amino 
butyric acid esters 
 
Figure 3.8: Synthesis of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl}, N-{5-ferrocenyl ethynyl-2-furanoyl}amino acid and dipeptide 
esters 105-138. 
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Table 3.6: N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-
naphthoyl}, N-{5-ferrocenyl ethynyl-2-furanoyl} amino acid and dipeptide esters 
105-138. 
R
1
 R
2
 Compound no. 
 
 
 
 
Gly Gly(OMe) 105 
GlyGly(OEt) 106 
Gly L-Ala(OMe) 107 
Gly L-Ala(OEt) 108 
Gly D-Ala(OMe) 109 
Gly D-Ala(OEt) 110 
GABA(OMe) 111 
GABA(OEt) 112 
Gly L-Phe(OEt) 113 
Gly L-Leu(OEt) 114 
Sar Gly(OEt) 115 
Sar Gly(OMe) 116 
Sar L-Ala(OEt) 117 
L-Pro Gly(OEt) 118 
L-Pro L-Ala(Oet) 119 
 
Gly Gly(OEt) 120 
Gly L-Ala(OEt) 121 
Sar L-Ala(OEt) 122 
L-Pro Gly(OEt) 123 
GABA(OEt) 124 
L-Pro L-Ala(Oet) 125 
Gly L-Leu(OEt) 126 
Sar Gly(OEt) 127 
Gly L-Phe(OEt) 128 
 
 
Gly Gly(OEt) 129 
Gly L-Ala(OEt) 130 
Gly D-Ala(OEt) 131 
Gly L-Phe(OEt) 132 
Gly L-Leu(OEt) 133 
Sar Gly(OEt) 134 
L-Pro Gly(OEt) 135 
L-Pro L-ala(OEt) 136 
Sar L-ala(OEt) 137 
GABA(OEt) 138 
   
 
71 
 
3.2.2. Preliminary cytotoxicological evaluation of the N-{para-(ferrocenyl) 
ethynyl benzoyl} amino acid and dipeptide esters  
 
The in vitro cytotoxicity of the derivatives 105-119 was initially tested at 10 µM in 
the H1299 lung cancer cell line. The results for the percentage growth of the H1299 
cell line compared to a DMSO control are depicted in Figure 3.9 and table 3.7. 
 
 
Figure 3.9: Percentage growth of H1299 cells after treatment of 10 µM of 
compounds 105-119. Growth is expressed relative to cells treated with an equivalent 
volume of DMSO. Error bars represent the standard deviation of triplicate 
experiments. 
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Table 3.7: Percentage growth at 10 µM on H1299 lung cancer cells for N-{para-
(ferrocenyl) ethynyl benzoyl} amino acid and dipeptide esters 105-119  
Ferrocenyl 
bioconjugate 
R Compound no. 
% growth  at 10 
µM 
 
 
Gly Gly(OMe) 105 66 ± 2.5 
Gly Gly(OEt) 106 30 ± 2.8 
Gly L-
Ala(OMe) 
107 78 ± 5.5 
Gly L-Ala(OEt) 108 5 ± 1.6 
Gly D-
Ala(OMe) 
109 77 ± 4.9 
Gly D-Ala(OEt) 110 28 ± 2.0 
GABA(OMe) 111 45 ± 3.4 
GABA(OEt) 112 15 ± 1.1 
Gly L-Phe(OEt) 113 72 ± 1.7 
Gly L-Leu(OEt) 114 47 ± 3.2 
Sar Gly(OEt) 115 53 ± 4.0 
Sar Gly(OMe) 116 75 ± 4.1 
Sar L-Ala(OEt) 117 15 ± 4.8 
L-Pro Gly(OEt) 118 38 ± 5.1 
L-Pro L-
Ala(OEt) 
119 13 ± 1.1 
 
From the preliminary screen at 10 μM a general trend can be observed, the methyl 
ester derivatives 105, 107, 109, 111, 116 inhibited cell growth by 22 ± 5.5 to 55 ± 
3.4 %  compared to the ethyl ester derivatives 106, 108, 110, 112, 113, 114, 115, 
117, 118, 119 which inhibited growth by 47± 4.0 to 95 ± 1.6 %. Thus, the methyl 
ester derivatives were not investigated further.  
A general trend was also observed in these derivatives, that is, the Gly L-Leu and 
Gly L-Phe ethyl esters inhibit growth by less that 53 %. For instance, the N-{para-
(ferrocenyl) ethynyl benzoyl} glycine L-phenylalanine ethyl ester 113 inhibited 
growth by 28 ± 1.7 % whilst the N-{para-(ferrocenyl) ethynyl benzoyl} glycine L-
leucine ethyl ester 114 inhibited growth by 53 ± 3.2 %. Thus, the Gly L-Leu and Gly 
L-Phe ethyl ester derivatives were not investigated further. As a result, it can be 
concluded that when chiral α-amino acids with bulky side chains are used as the 
second amino acid in the dipeptide moiety, a loss of anti-proliferative activity is 
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observed for this particular group of compounds. Compounds 106, 108, 110, 112, 
117, 118 and 119 inhibited growth by greater than 60 %. Therefore, IC50 values were 
determined for these compounds. 
 
3.2.3 Preliminary cytotoxicological evaluation of the N-{6-(ferrocenyl) ethynyl-
2-naphthoyl} amino acid and dipeptide esters  
 
The in vitro anti-proliferative effect of compounds 120-128 were studied at a 
concentration of 10 µM in the H1299 lung cancer cells. The results of this biological 
study are shown in figure 3.10 and table 3.8. From the preliminary screen a general 
trend was observed, the Gly L-Leu 126 and Gly L-Phe 128 ethyl esters inhibited 
growth by less than 34 %.  Thus, the Gly L-Leu and Gly L-Phe ethyl ester 
derivatives were not investigated further. Compounds 120, 121, 122, 123, 124, 125 
and 127 inhibited growth by greater than 67 %. Therefore, IC50 values were 
determined for these compounds.  
 
 
Figure 3.10: Percentage growth of H1299 cells after treatment of 10 µM of 
compounds 120-128. Growth is expressed relative to cells treated with an equivalent 
volume of DMSO. Error bars represent the standard deviation of triplicate 
experiments. 
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Table 3.8: Percentage growth at 10 µM on H1299 lung cancer cells for N-{para-
(ferrocenyl) ethynyl naphthoyl} amino acid and dipeptide esters 120-128. 
Ferrocenyl bioconjugate R Compound no. 
% growth at 
10 µM 
 
Gly Gly(OEt) 120 11 ± 1.2 
Gly L-Ala(OEt) 121 16 ± 5.3 
Sar L-Ala(OEt) 122 6 ± 1.0 
L-Pro Gly(OEt) 123 18 ± 1.92 
GABA(OEt) 124 32 ± 5.8 
L-Pro L-
Ala(Oet) 
125 6 ± 0.6 
Gly L-Leu(OEt) 126 67 ± 4.7 
Sar Gly(OEt) 127 10 ± 1.4 
Gly L-Phe(OEt) 128 71 ± 2.53 
 
3.2.4 Preliminary cytotoxicological evaluation of the N-{5-(ferrocenyl) ethynyl-
2-furanoyl} amino acid and dipeptide esters   
 
The in vitro cytotoxicity of the derivatives 129-138 against the human lung 
carcinoma cell line H1299 was evaluated by the acid phosphatase assay and the % 
growth inhibition achieved by the derivatives are depicted in figure 3.11 and table 
3.9.  
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Figure 3.11: Percentage growth of H1299 cells after treatment of 10 µM of 
compounds 129-138. Growth is expressed relative to cells treated with an equivalent 
volume of DMSO. Error bars represent the standard deviation of triplicate 
experiments. 
Table 3.9: Percentage growth of H1299 lung cancer cells treated with 10 µM N-
{para-(ferrocenyl) furanoyl naphthoyl} amino acid and dipeptide esters 129-138. 
Ferrocenyl 
bioconjugate 
R 
Compound 
no. 
% growth at 10 
µM 
 
 
Gly Gly(OEt) 129 62 ± 2.6 
Gly L-Ala(OEt) 130 87 ± 3.4 
Gly D-Ala(OEt) 131 87 ± 4.4 
Gly L-Phe(OEt) 132 91 ± 3.3 
Gly L-Leu(OEt) 133 89 ± 3.7 
Sar Gly(OEt) 134 82 ± 5.4 
L-Pro Gly(OEt) 135 83 ± 2.3 
L-Pro L-ala(Oet) 136 78 ± 2.6 
Sar L-ala(OEt) 137 83 ± 1.5 
GABA(OEt) 138 87 ± 1.4 
 
From the preliminary screen at 10 μM, all derivatives showed little effect on growth, 
with growth inhibition between 9 ± 3.3 and 38 ± 2.6 %. In the case of the N-{5-
(ferrocenyl) ethynyl-2-furanoyl} glycine glycine ethyl ester 129, it achieved the 
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highest inhibition of growth of 38 ± 2.6 % and thus, an IC50 value for 129 was 
determined. For compounds 130-138 no further investigation were carried out. 
 
3.2.5 IC50 value determination of N-{para-(ferrocenyl) ethynyl benzoyl} amino 
acid and dipeptide esters  
 
Further studies were conducted as described in Section 3.1.3 to determine IC50 
values for the H1299 cell line. The IC50 value for each compound was calculated 
using Calcusyn software, and standard deviations were calculated using data 
obtained from three independent experiments. The values obtained are listed in table 
3.10. 
 
Table 3.10:  IC50 values for selected compounds, carboplatin and cisplatin H1299 
cells. 
Compound Name                                                                        No.          IC50 (µM) 
 
Cisplatin 
 
 
8 
 
1.5 ± 0.1 
 
Carboplatin 
 
9 10.0 ± 1.6 
 
 
N-{para-(ferrocenyl) ethynyl benzoyl} Gly Gly(OEt)   
 
106 
 
6.9 ± 2.1 
 
N-{para-(ferrocenyl) ethynyl benzoyl} Gly L-Ala(OEt)   108 3.8 ± 1.9 
 
N-{para-(ferrocenyl) ethynyl benzoyl} Gly D-Ala(OEt)   110 6.1 ± 3.4 
 
N-{para-(ferrocenyl) ethynyl benzoyl} GABA(OEt)    112 4.9 ± 4.1 
 
N-{para-(ferrocenyl) ethynyl benzoyl} Sar L-Ala(OEt)   117 7.1 ± 2.5 
 
N-{para-(ferrocenyl) ethynyl benzoyl} L-Pro Gly(OEt) 118 
 
8.3 ± 3.1 
 
N-{para-(ferrocenyl) ethynyl benzoyl} L-Pro L-Ala(OEt)    119 5.7 ± 2.9 
 
 
From the IC50 values of compounds 106, 108, 110, 112, 117, 118 and 119 all exert a 
cytotoxic effect on the H1299 lung cancer cell line. All seven derivatives have an 
IC50 value that is lower than 9 µM and more cytotoxic in vitro than carboplatin. The 
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most active compound was N-{para-(ferrocenyl) ethynyl benzoyl} glycine L-alanine 
ethyl ester 108 which had an IC50 value of 3.8 ± 1.9 µM.  
The in vitro cytotoxicity of cisplatin was also evaluated in the H1299 cell line and 
the IC50 value was determined to be 1.5 ± 0.1 µM. Thus, compounds 106, 108, 110, 
112, 117, 118 and 119 are less cytotoxic in vitro than cisplatin.  
Previously, in vitro cytotoxic assays have shown the N-(ferrocenyl) naphthoyl 
derivatives to be more active than the N-(ferrocenyl) benzoyl derivatives with the 
most active derivative, N-{6-(ferrocenyl)-2-napthoyl} glycine glycine ethyl ester 
displaying an IC50 value of 0.13 ± 0.01 µM [131]. For the N-{para-(ferrocenyl) 
ethynyl benzoyl} glycine glycine ethyl ester, an IC50 value of 6.9 ± 5.1 µM was 
obtained. Thus, it can be concluded that the presence of the ethynyl moiety did not 
result in an increase in the cytoxicity of the N-{para-(ferrocenyl) ethynyl benzoyl} 
amino acid and dipeptide esters, when compared to the N-(ferrocenyl) benzoyl and 
naphthoyl analogues previously reported [126-130]. 
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3.2.6 IC50 value determination of N-{6-(ferrocenyl) ethynyl-2-naphthoyl} amino 
acid and dipeptide esters  
 
The IC50 values for derivatives 120-128 were determined by the acid phosphatase 
assay as previously described in section 3.2.3. The IC50 values for derivatives 120-
127 relative to cisplatin and carboplatin are depicted in table 3.11. 
 
Table 3.11: IC50 values for selected compounds, carboplatin and cisplatin in H1299 
cells.  
Compound Name                                                                        No.          IC50 (µM) 
 
Cisplatin 
 
 
8 
 
1.5 ± 0.1 
 
Carboplatin 
 
9 10.0 ± 1.6 
 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} Gly Gly(OEt)   
 
120 
 
5.0 ± 4.1 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} Gly L-Ala(OEt)   121 5.0 ± 3.6 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} Sar L-Ala(OEt)    122 3.2 ± 2.6 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} L-Pro Gly(OEt)    123 5.1 ± 1.4 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} GABA(OEt)    124 7.2 ± 1.5 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} L-Pro L-Ala(OEt)    125 3.8 ± 2.0 
 
N-{6-(ferrocenyl) ethynyl-2-naphthoyl} Sar Gly(OEt)   127 4.7 ± 3.7 
 
 
From the IC50 values of the N-{6-(ferrocenyl) ethynyl-2-naphthoyl} amino acid and 
dipeptide ethyl esters 120, 121, 122, 123, 124, 125 and 127, all exert a cytotoxic 
effect on the H1299 lung cancer cell line. All seven derivatives have an IC50 value 
that is lower than 7.3 µM and more cytotoxic in vitro than carboplatin. The most 
active compound was N-{6-(ferrocenyl) ethynyl-2-naphthoyl} sarcosine L-alanine 
ethyl ester 122 which had an IC50 value of 3.2 ± 2.6 µM. 
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3.2.7 IC50 value determination of N-{5-(ferrocenyl) ethynyl-2-furanoyl}-glycine-
glycine ethyl ester 129.   
 
The N-{5-(ferrocenyl) ethynyl-2-furanoyl} glycine glycine ethyl ester 129 was the 
only derivative of the N- {para-(ferrocenyl) furanoyl naphthoyl} amino acid and 
dipeptide esters series to be tested to determine the IC50 value (table 3.12). 
 
Table 3.12: IC50 values for 129, carboplatin and cisplatin in H1299 cells. 
Compound Name                                                                       No.            IC50(µM) 
 
Cisplatin 
 
8 1.5 ± 0.1 
 
Carboplatin 
 
9 10 ± 1.6 
 
N-{5-(ferrocenyl) ethynyl-2-furanoyl} Gly Gly(OEt)   129 
 
23 ± 5.1 
 
 
From the results obtained, compound 129 displayed an IC50 value of 23 ± 5.1 µM 
and was less cytotoxic in vitro than cisplatin or carboplatin. In addition, when 
compared to the N-{para-(ferrocenyl) ethynyl benzoyl} 106 and N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl} glycine glycine ethyl esters 120 with IC50 values of 6.9 ± 2.1 
µM and 5.0 ± 4.1 µM respectively, compound 129 was also less cytotoxic. As a 
result it can be concluded that the furanoyl ring is not a bioactive aromatic conjugate 
linker that promotes anti-proliferative activity in the H1299 lung cancer line.  
 
3.2.8 Conclusion 
 
The cytotoxicological evaluation of N-{para-(ferrocenyl) ethynyl benzoyl}, N-{6-
(ferrocenyl) ethynyl-2-naphthoyl} and N-{5-(ferrocenyl) ethynyl-2-furanoyl} amino 
acid and dipeptide esters was carried out in the H1299 lung cancer cell line. The 
most active derivative N-{6-(ferrocenyl) ethynyl-2-naphthoyl} sarcosine L-alanine 
ethyl ester 122 displayed an IC50 value of 3.2 ± 2.6 µM. This compound is more 
active than the clinically used carboplatin but is less effective than cisplatin. A 
general trend can be seen between the N-{para-(ferrocenyl) ethynyl benzoyl} and N-
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{6-(ferrocenyl) ethynyl-2-naphthoyl} amino acid and dipeptide esters. The Gly Gly, 
Sar L-Ala, L-Pro Gly, L-Pro L-Ala ethyl esters of the N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} derivatives are more active than the N-{para-(ferrocenyl) ethynyl 
benzoyl} derivatives whilst the Gly L-Ala and GABA esters of the N-{para-
(ferrocenyl) ethynyl benzoyl} derivatives are more active than the N-{6-(ferrocenyl) 
ethynyl-2-naphthoyl} derivatives. 
From the SAR studies carried out it has been clearly demonstrated that the presence 
of the ethynyl moiety does not result in any significant enhancement of the anti-
proliferative effect of the N-(ferrocenyl) benzoyl and naphthoyl dipeptide 
derivatives. However, the incorporation of a methyl derivative to the unsubstituted 
cyclopentadiene ring of the N-(ferrocenyl) benzoyl dipeptide derivatives showed an 
enhancement of the anti-proliferative effect. Thus, the incorporation of a methyl 
group in the most active N-{6-(ferrocenyl)-2-napthoyl} glycine glycine ethyl ester 
31 (IC50 value of 0.13 ± 0.01 µM) could result in the formulation of a potent novel 
bioorganometallic anticancer agent. 
 
3.3 Cytotoxicological evaluation of N-{6-ferrocenyl-2-naphthoyl}-glycine-
glycine- compounds with altered ester moiety 
 
3.3.1 Introduction  
 
To date Dr Peter Kenny’s group have shown that the replacement of the conjugated 
linker of N-(ferrocenyl) benzoyl dipeptide esters with a naphthoyl linker leads to an 
improvement in antiproliferative effect in the non small cell lung cancer (NSCLC) 
cell line, H1299. They synthesized a number of novel compounds with varying 
lengths of ester residues with marked variety in activity. 
Ferrocene: Ferrocene acts as an electroactive core. It has a low oxidation potential 
and reversible redox potential which are believed to be important for anti-
proliferative effect. In the SAR study of the 1-alkyl-1’ derivatives, incorporation of a 
methyl derivative to the unsubstituted cyclopentadiene ring of the ferrocene 
molecule enhanced the anti-proliferative effect of the ferrocenyl dipeptide 
bioconjugates. The most active derivative was the 1-methyl-1’-N-{meta-(ferrocenyl) 
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benzoyl} glycine glycine ethyl ester 68 which displayed an IC50 value of 2.6 ± 0.6 
µM. 
Conjugated linker: The conjugated linker was considered to be the most 
fundamental region that may be altered, since the conjugating ability of the linker is 
important in determining the redox potential of the derivative. Previous studies have 
shown that the replacement of the conjugated linker of N-(ferrocenyl) benzoyl 
dipeptide esters with a naphthoyl linker leads to an improvement in antiproliferative 
effect in the non small cell lung cancer (NSCLC) cell line, H1299 [132-134].
 
From 
the series of N-(ferrocenyl) naphthoyl amino acid and dipeptide ethyl esters reported, 
the N-{6-(ferrocenyl)-2-napthoyl} glycine glycine ethyl ester 31 displayed an IC50 
value of 0.13 ± 0.01 µM in the H1299 lung cancer cell  line.  
Peptide chain: In relation to the peptide chain, the 20 essential α-amino acids 
provide a great assortment of side chain functional groups. The previous study 
indicated that anti-proliferative effect is best when the small, neutral α-amino acid 
glycine is present in the peptide chain.  
Ester group: Previously it was thought that the ester portion of the compound did 
not play a role in the activity of the compound but instead may have downstream 
applications such as oral absorption and biodistribution. The objective of this SAR 
study was to determine if there is any relationship between the ester moiety and 
biological activity. 
 
82 
 
Fe
NH2
+
Fe
O
OMe
O
OMe
Fe
O
OH
Fe
O
NH
HN
O
O
OR
(i)
(ii)
(iii)
R= H, Me, Pr, Bu, Bn  
(i) NaNO2, HCl, 5 °C; (ii) NaOH/MeOH, H2O; (iii) EDC, NHS, 
Et3N, amino acid/dipeptide ester. 
Figure 3.12: The general reaction scheme for the synthesis of N-{6-ferrocenyl-2-
naphthoyl}-glycine-glycine- compounds with altered ester moiety. 
 
 
Figure 3.13: General structure of constituent regions of N-{6-ferrocenyl-2-
naphthoyl}-glycine-glycine- compounds with altered ester moiety. 
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3.3.2  Preliminary screening of N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine- 
compounds with altered ester moiety 
  
The compound N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester (31) has 
previously been shown to be the most active bioconjugate synthesised by this group 
to date with IC50 values of 0.13 ± 0.02 and 1.10 ± 0.13 in H1299 and Sk-Mel-28 
respectively. A series of derivatives were synthesized based on 31 with a modified 
ester moiety. To assess if any of these compounds were biologically active, a 
comprehensive screen of every compound at a single dose (10 μM) was performed in 
a panel of cell lines which included 3 melanoma cell lines; HT-144, Lox-IMVI and 
Malme-3M and 2 lung cancer call lines; A549 and H1299. The results for the 
preliminary screen of N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl, ethyl, 
propyl, butyl, benzyl 30–34 are depicted in figure 3.14 and table 3.13. 
 
Figure 3.14: Effect of N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine- compounds 
with modified ester group (30-34) at 10 µM. Growth is expressed relative to cells 
treated with an equivalent volume of DMSO. Error bars represent the standard 
deviation of triplicate assays. 
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Table 3.13: Percentage growth of cell lines, HT-144, Lox-IMVI, Malme-3M, A549 
and H1299, when treated with 10 µM N-{6-ferrocenyl-2-naphthoyl}-glycine-
glycine- compounds with modified ester group 30-34. 
Compound 
Compoun
d 
No. 
Cell Line 
% 
growth 
at 10 
µM 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OMe 30 
HT-144 7.0 ± 1.6 
Lox-IMVI 3.0 ± 1.3 
Malme-3M 2.1 ± 0.1 
A549 10.2 ± 1.4 
H1299 4.7 ± 1.0 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OEt 31 
HT-144 9.2 ± 2.3 
Lox-IMVI 4.0 ± 2.4 
Malme-3M 2.1 ± 0.1 
A549 9.4 ± 1.2 
H1299 2.9 ± 0.6 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OPr 32 
HT-144 9.1 ± 1.2 
Lox-IMVI 2.1 ± 1.4 
Malme-3M 2.1 ± 0.1 
A549 5.1 ± 3.3 
H1299 2.5 ± 0.1 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OBu 33 
HT-144 9.2 ± 1.1 
Lox-IMVI 3.0 ± 1.5 
Malme-3M 2.1 ± 0.1 
A549 5.2 ± 3.0 
H1299 2.5 ± 0.1 
 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OBn 
 
34 
HT-144 9.7 ± 0.7 
Lox-IMVI 3.1 ± 1.5 
Malme-3M 2.2 ± 0.1 
A549 23.8 ± 5.2 
H1299 2.7 ± 0.0 
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The results of the preliminary screen at 10 µM (table 3.13) show that, with the 
exception of N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OBn 34 and N-{6-
ferrocenyl-2-naphthoyl}-glycine-glycine-OMe 30 in A549 cells, all derivatives 
exhibit growth inhibitions levels > 90 %. 
It can also be seen that for every compound 30-34, cell lines HT-144 and A549 
exhibit a lower sensitivity in each case when compared to Lox-IMVI, Malme-3M 
and H1299. For example, the N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OBu 33 
show a % growth inhibition at 10 µM between 97.0 – 97.9 % in cell lines Lox-IMVI, 
Malme-3M and H1299 but showed a lower % growth inhibition at 10 µM in A549 at 
94.8 ± 3.0 % and even lower % growth inhibition in HT-144 cells at 90.8 ± 1.1 %. 
The 10 µM preliminary screen confirmed activity for each compound with the ester 
moiety exhibiting little difference in activity. A secondary screening was performed 
at 1 µM with all other conditions remaining the same in an attempt to identify any 
difference in activity at a lower concentration. 
 
From the results of the 1 µM screen a clearer idea of the difference in activity levels 
of compounds 30-34 can be seen. Compounds 32-34 show no appreciable effect on 
the growth of any of the cell lines at 1 µM. Compounds 30 and 31 reduce cell growth 
to below 40 % across all cell lines with 30 having the greatest antiproliferative effect 
at 1 µM. 
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Figure 3.15: Effect of N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine- compounds 
with modified ester group at 1 µM. Growth is expressed relative to cells treated with 
an equivalent volume of DMSO. Error bars represent the standard deviation of 
triplicate assays. 
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Table 3.14: Percentage growth of cell lines, HT-144, Lox-IMVI, Malme-3M, A549 
and H1299, with 1 µM N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine- compounds 
with modified ester group 30-34 
Compound 
Compound 
No. Cell Line 
% growth 
at 10 µM 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OMe 30 
HT-144 10.8 ± 2.9 
Lox-IMVI 17.0 ± 2.6 
Malme-3M 29.5 ± 3.2 
A549 12.9 ± 0.4 
H1299 16.9 ± 2.0 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OEt 31 
HT-144 22.8 ± 2.0 
Lox-IMVI 20.6 ± 4.7 
Malme-3M 34.7 ± 3.5 
A549 24.8 ± 1.9 
H1299 21.5 ± 3.3 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OPr 32 
HT-144 94.0 ± 2.3 
Lox-IMVI 96.4 ± 3.4 
Malme-3M 94.8 ± 6.3 
A549 93.2 ± 1.8 
H1299 93.6 ± 4.0 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OBu 33 
HT-144 97.3 ± 4.2 
Lox-IMVI 98.4 ± 3.6 
Malme-3M 93.7 ± 6.5 
A549 96.1 ± 3.4 
H1299 93.7 ± 5.2 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine-OBn 34 
HT-144 95.1 ± 4.8 
Lox-IMVI 96.5 ± 2.3 
Malme-3M 
92.6 ± 
11.7 
A549 96.4 ± 7.9 
H1299 92.6 ± 6.6 
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3.3.3 Cytotoxicological evaluation of N-{6-ferrocenyl-2-naphthoyl}-glycine-
glycine methyl ester (30) and N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl 
ester (31) 
 
To get a better insight into the efficacy of these compounds, the two most active, N-
{6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl ester (30) and N-{6-ferrocenyl-
2-naphthoyl}-glycine-glycine ethyl ester (31) were selected for further analysis.  
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl 31 has previously been 
evaluated for anti-proliferative activity in H1299 cells and achieved an IC50 of 0.13 ± 
0.01 µM. The cell line panel has been expanded to include melanoma cell lines; 
Malme-3M, Lox-IMVI and HT-144 as well as lung cancer cell line, A549, and tested 
sensitivity to 30 and 31 (Figure 3.16 and 3.17).  
 
 
Figure 3.16: Inhibition curve of N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine 
methyl ester (30) in cell lines H1299, Malme-3M, Lox-IMVI, HT-144 and A549. 
Growth is expressed relative to cells treated with an equivalent volume of DMSO. 
Error bars represent the standard deviation of triplicate experiments. 
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Figure 3.17: Dose response curve for N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine 
ethyl ester (31) in H1299, Malme-3M, Lox-IMVI, HT-144 and A549. Growth is 
expressed relative to cells treated with an equivalent volume of DMSO. Error bars 
represent the standard deviation of triplicate experiments. 
 
IC50 values were determined in the panel of cell lines H1299, Malme-3M, Lox-
IMVI, HT-144 and A549 for compounds 30 and 31, as well as cisplatin which is 
used as a reference compound to assess relative levels of anti-proliferative activity 
(table 3.15). Both 30 and 31 show lower IC50 values (which is indicative of higher 
anti-proliferative activity) when compared to cisplatin. Also, in all cell lines, 30 
shows lower IC50 values than 31. The IC50 values of 30 are consistent across cell 
types, ranging from 0.2 ± 0.02 to 0.3 ± 0.05 µM. In comparison, IC50 values for 31 
range from 0.5 ± 0.02 to 1.4 ± 0.21 µM. It is note-worthy that the IC50 value for 31 
in H1299 is recorded at 1.4 ± 0.21 µM but was previously reported as 0.13 ± 0.01 
µM in the same cell line, a > 10 fold lowering of growth inhibition activity. Potential 
reasons for this are discussed in section 4.1.3. 
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Table 3.15: IC50 values for N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl 
ester (31) and N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl ester (30) in 
H1299, Malme-3M, Lox-IMVI, HT-144 and A549. Cisplatin is used as a reference. 
Standard deviations for triplicate assays are presented.  
 A549 
(µM) 
H1299 
(µM) 
HT-144 
(µM) 
Lox-IMVI 
(µM) 
Malme-3M 
(µM) 
Cisplatin 2.6 ± 0.1 2.1 ± 0.2 3.0 ± 0.4 2.9 ± 0.9 2.7 ± 0.5 
30 0.7 ± 0.07 1.4 ± 0.21 0.5 ± 0.06 0.5 ± 0.04 0.5 ± 0.02 
31 0.2 ± 0.03 0.3 ± 0.04 0.2 ± 0.02 0.2 ± 0.06 0.3 ± 0.05 
 
3.3.4 Activity of 6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl ester (30) 
and N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl (31) in cisplatin and 
temozolomide resistant cell lines 
 
Intrinsic and acquired resistance are a common problem with chemotherapeutics and 
are a major hurdle to effective cancer treatment. Often resistance to one 
chemotherapeutic agent can also play a role in resistance to others due to similarities 
in modes of action, this is referred to as cross-resistance. N-{6-ferrocenyl-2-
naphthoyl}-glycine-glycine methyl and ethyl ester (30, 31) were evaluated in a 
melanoma cell line model of acquired temozolomide (TMZ) resistance (Malme-
3M/TMZ) and a lung cancer cell line model of cisplatin resistance (A549/Cpt) 
(figures 3.18 and 3.19). 
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Figure 3.18: Effect of N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl ester 
on growth of A549 and Malme-3M cells compared to their resistant variants 
A549/Cpt and Malme-3M/TMZ, respectively Error bars represent the standard 
deviation of triplicate assays. 
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Figure 3.19: Effect N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl 31 on 
growth of A549 and Malme-3M cells compared to their resistant variants A549/Cpt 
and Malme-3M/TMZ, respectively Error bars represent the standard deviation of 
triplicate assays. 
 
The IC50 values of 30 and 31 were evaluated in A549 and its cisplatin resistant 
derivative and Malme-3M and its temozolomide resistant derivative (table 3.16). 
IC50 values of cisplatin and temozolomide were also determined to confirm the 
resistant phenotype of the cells. The A549/Cpt cell line showed 1.72 fold resistance 
to cisplatin compared to the parental A549 cells. The Malme-3M/TMZ showed 2.3 
fold ressistance to temozolomide compared to the parental Malme-3M cells. There 
was cross resistance in both resistant cell lines to compound 30 with IC50 values 
increasing from 0.7 ± 0.04 µM in A549 cells to 2.4 ± 0.6 µM in A549/Cpt cells (3.4 
fold resistance) and from 0.5 ± 0.1 µM in Malme-3M cell to 2.8 ± 0.5 µM in Malme-
3M/TMZ cells (5.6 fold resistance). A 2 fold increase in IC50 value was observed for 
31 in A549/Cpt cells compared to A549 cells, from 0.2 ± 0.04 µM to 0.4 ± 0.1 µM 
but no difference in IC50 value was observed between Malme-3M/TMZ and Malme-
3M, suggesting that 31 may overcome the mechanisms of acquired temozolomide 
resistance in this cell line model. 
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Table 3.16: IC50 values for N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl 
ester (30) and N-{para-(ferrocenyl)cinamoyl}-glycine-glycine ethyl ester (31) in 
A549 and its cisplatin resistant derivative (A549/Cpt), and Malme-3M and its 
temozolomide resistant derivative (Malme-3M/TMZ). IC50 values are also given for 
cisplatin and temozolomide where appropriate as a reference. Standard deviations for 
triplicate assays are presented.  
 Cisplatin 
(µM) 
30 
(µM) 
31 
(µM) 
Temozolomide 
(µM) 
A549 3.6 ± 0.7 0.2 ± 0.04 0.7 ± 
0.04 
 
A549/Cpt 6.2 ± 0.9 0.4 ± 0.1 2.4 ± 0.6  
Malme-3M  0.3 ± 0.05 0.5 ± 0.1 209 ± 27 
Malme-3M/TMZ  0.3 ± 0.1 2.8 ± 0.5 483 ± 32 
 
3.3.5 Effect of 6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl ester (30) on 
the cell cycle in A549 and HT-144 cells 
 
The growth and division of cells proceeds via the cell cycle, which is typically 
divided into four distinct stages: the synthesis (S), mitosis (M) and two gap (G1 and 
G2) phases. Most normal cells, unless they have received a stimulus to proliferate or 
differentiate, exist in a non-dividing, quiescent state known as G0. [269] Cancer 
cells, on the other hand, grow at an uncontrolled rate. As the cell progresses from the 
G1 to the S phase the cell must decide whether to divide into two daughter cells or 
die, as the cell can only exist in subsequent phases for a short period. Many 
chemotherapeutic agents, including ciplatin, function by blocking cell cycle 
progression after this restriction point [270]. 
The progression of cells through the cell cycle can be tracked using a propidium 
iodide stain. The stain is a fluorescent molecule that intercalates with DNA in the 
cell nucleus. Discrimination between the various stages of the cell cycle is possible 
due to changes in the concentrations of DNA in the cells as the cycle progresses. 
Resting cells (G0/G1 phase) contain two copies of each chromosome. As the cells 
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progress towards mitosis, they synthesise DNA (S phase), which allows for more 
intercalation and increases the fluorescence intensity. When all chromosomes have 
been replicated, the DNA content has doubled (G2/M phase), and thus, the cells 
fluoresce with twice the intensity of the G0/G1 phase. Cells in which the DNA has 
become fragmented or degraded (such as apoptotic cells) will exhibit a decrease in 
fluorescence intensity, compared to the G0/G1 phase. These cells will appear as a 
broad “sub-G0/G1” peak, and can represent, in addition to apoptotic cells, nuclear 
fragments, clumps of chromosomes, micronuclei or cells undergoing differentiation 
[271]. A flow cytometer is then used to analyse the DNA content of the cell to 
determine what phase the cells are at. 
In both A549 (Figure 3.20) and HT-144 (Figure 3.21) cell lines, compound 30 most 
notably caused a significant increase of cells in the sub G0 fraction of the cell cycle. 
This is most evident in the HT-144 cell line where there is an increase from 1.7 % of 
cells in the sub G0 fraction of control cells to 55.4 % of cells treated with 2µM of 30.  
This suggests that the primary mode of action of 30 is induction of cell apoptosis 
and/or necrosis. A small increase in G1 arrest was also observed in A549 cells but not 
in HT-144 cells. In both cell lines, the percentage of cells in the S and G2/M phases 
decreases with increasing concentrations of compound 30. In both cell lines the most 
noticeable aspect is the strongly significant correlation between compound 
concentration and cells in the Sub G0 fraction from concentration of 0.125 µM and 
above. This is an indication of cells undergoing apoptosis/necrosis. 
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Figure 3.20: Percentage of A549 cells in the Sub G0, G1/G0, S and G2/M phases of 
cell cycle after 72 hours treatment with N-{6-ferrocenyl-2-naphthoyl}-glycine-
glycine methyl ester 30. Error bars represent the standard deviation of triplicate 
assays. “*” indicates p < 0.05, “**” indicates p < 0.01 for treated cells compared to 
controls, using the Student’s T-test 
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Figure 3.21: Percentage of HT-144 cells in the Sub G0, G1/G0, S and G2/M phases of 
cell cycle after 72 hours treatment with N-{6-ferrocenyl-2-naphthoyl}-glycine-
glycine methyl ester 30. Error bars represent the standard deviation of triplicate 
assays. . “*” indicates p < 0.05, “**” indicates p < 0.01 for treated cells compared to 
controls, using the Student’s T-test 
 
3.3.6 Effect of 6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl ester (30) on 
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assay determines mid- to late- stage apoptosis when DNA fragmentation is occurring 
in cells. The DNA degradation generates DNA strands with exposed 3'-hydroxyl 
ends and terminal deoxynucleotidyl transferase (TdT) catalyses the incorporation of 
bromodeoxyuridine (BrdU) residues into the fragmenting nuclear DNA at the 3'-
hydroxyl ends by nicked end labeling. A TRITC-conjugated anti-BrdU antibody can 
then label the 3'-hydroxyl ends for detection by a Guava System. 
For both A549 (Figure 3.22) and HT-144 (Figure 3.23) cell lines, increasing 
concentrations of compound 30 caused an increase in apoptosis induction. A 
dramatic increase in apoptosis induction was observed when the concentration was 
increased from 0.25 µM to 0.5 µM, 15.0 ± 9.7 % to 66.8 ± 8.8 % for A549 cells and 
12.7 ± 3.2 % to 59.8 ± 4.5 % in HT-144, suggesting that a threshold concentration 
between 0.25 and 0.5 µM is required for efficient induction of cell death. In both cell 
lines, there is a strongly significant correlation between compound concentration and 
% of apopototic cells with p-values of < 0.01. 
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Figure 3.22: Measurement of N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl 
ester induced apoptosis in A549 after 72 hours of treatment using the TUNEL assay. 
A control of equivalent DMSO concentration is used to ensure that DMSO does not 
contribute to apoptosis levels. Error bars represent the standard deviation of triplicate 
assays. . “*” indicates p < 0.05, “**” indicates p < 0.01 for treated cells compared to 
controls, using the Student’s T-test 
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Figure 3.23: Measurement of N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl 
ester induced apoptosis in HT-144 after 72 hours of treatment using the TUNEL 
assay. A control of equivalent DMSO concentration is used to ensure that DMSO 
does not contribute to apoptosis levels.  Error bars represent the standard deviation of 
triplicate assays. . “*” indicates p < 0.05, “**” indicates p < 0.01 for treated cells 
compared to controls, using the Student’s T-test 
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3.3.7 Effect of 6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl ester (30) and 
N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl (31) on Normal Human 
Dermal Fibroblast (NHDF) cells. 
 
Normal Human Dermal Fibroblast (NHDF) cells are isolated from juvenile foreskin. 
They are often used in wound healing studies and dermatological research however 
they also have a role in cancer research, as control normal cells. Most chemotherapy 
regimens rely, at least partially, on the cytotoxic properties that eliminate cancerous 
cells. The desirable anti-proliferative effects of chemotherapeutic drugs also have an 
effect on healthy cells of the body, which often result in side-effects. It is a trade-off 
between the anti-proliferative effects in cancerous cells and in healthy cells. For that 
reason the effect of N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl ester (30) 
and N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl ester (31) on NHDF cells 
(Table 3.17) was comapred. Cisplatin was used as a reference.  
 
Table 3.17: IC50 values for N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine methyl 
ester (30) and N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl ester (31) and 
reference compound cisplatin, in Normal Human Dermal Fibroblast (NHDF) cells. 
Standard deviations for triplicate assays are presented. Student’s t-test was 
performed to determine significant differences between treatments and cell that were 
treated with cisplatin. * denotes p ≤ 0.05 
 30 (µM) 31 (µM) Cisplatin (µM) 
NHDF 12.0 ± 3.8 14.2 ± 2.4* 10.0 ± 1.8 
 
The cisplatin IC50 value was determined to be 10.0 ± 1.8 µM. In contrast, the IC50 
values for compounds 30 and 31 of 12.0 ± 3.8 and 14.2 ± 2.5 µM, respectively. Due 
to overlapping standard deviations, 31 is significantly less cytotoxic than cisplatin 
however it cannot be shown that 30 is significantly less or more cytotoxic than 
cisplatin. 
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3.3.8 Conclusions 
 
After selecting the two most active compounds from the initial screen in table 3.14 
for further analysis a number of properties associated with the mechanism of action 
of these compounds was determined. After expanding the cell line panel, it can be 
seen that the activity is not confined to a single cancer type but is effective across, 
but not limited to, melanoma and lung. Across all cell lines compound (30) is more 
effective than (31).  It is worth noting that both of the lead compounds surpass the 
level of activity of cisplatin in all cell lines, excluding NHDF. 
To investigate the potential of these compounds to overcome resistance to DNA 
damaging chemotherapy drugs, the IC50 values for the two compounds in A549 and 
Malme-3M cells was comapred and their cisplatin and temozolomide resistant 
derivatives, respectively. Compound 30 shows susceptibility to cross resistance with 
both cisplatin and temozolomide, with greater than three-fold resistance in the 
cisplatin resistant A549 cells and greater than five-fold resistance in the 
temozolomide resistant Malme-3M cells. Compound 31 may exhibit slight cross-
resistance in A549/Cpt cells but Malme-3M/TMZ appears to retain sensitivity to 31. 
Cell cycle analysis suggests that compound 30 induces slight G1 arrest in A549 cells 
but the predominant effect observed was an increase in the sub-G0 fraction, in both 
cell lines tested. 
The results of the cell cycle assay were reinforced by the results of the apoptosis 
assay. Late stage apoptosis is shown in a dose dependent manner using the TUNEL 
assay. In both A549 and HT-144 cell lines there is a significant increase in apoptosis 
induction particularly at concentrations higher than 0.5 µM. 
The cytotoxicity of 30 and 31 was analysed in normal cells and compared against 
cisplatin as a reference for the levels of toxicity observed with chemotherapy drugs 
used in clinical practice. Similar IC50 values were observed for compounds 30 and 31 
but the values were higher than observed in the cancer cell lines (table 3.15), 
suggesting selective anti-cancer activity.  This analysis would suggest that the 
ferrocenyl compounds are potential anti-cancer compounds with greatly reduced 
toxicity to normal cells.  
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3.4 Solubility 
 
3.4.1 Biological solvents/excipients/vehicles/carriers 
 
The potential of a number of solvents to be used to reduce the level of DMSO used 
for the administration of ferrocenyl compounds was tested by first dissolving N-{6-
ferrocenyl-2-naphthoyl}-glycine-glycine ethyl ester 31 in DMSO to a concentration 
of 8 mg/mL. This was then diluted with the relevant vehicle to a 1 in 4 solution 
which would give a working stock solution of 2 mg/mL. This solution was then 
analysed in A549 cells at a concentration of 1 µM as the % growth inhibition 
achieved with 1 µM of 31 when dissolved in 100 % DMSO is already known to be 
75.2 ± 1.9 % (table 3.14). A control was used for each vehicle, in which a 25 % 
DMSO/ 75 % vehicle solution was tested to ensure that this had no anti-proliferative 
effect on the cells. 
 
Table 3.18: Percentage growth of A549 cell after treatment with 1 µM N-{6-
ferrocenyl-2-naphthoyl}-glycine-glycine ethyl ester 31 using a variety of vehicles for 
delivery. A control group was also tested which used an equivalent concentration of 
vehicle without 31.  
Vehicle (25 % DMSO) % growth 
 Control 31 (1 µM) 
80 mM citrate buffer 98.8 % 83.8 % 
5 % Carboxymethyl Cellulose 98.9 % 86.0 % 
1 % Carboxymethyl Cellulose 96.8 % 60.2 % 
50 % Propylene Glycol Solution 103.1 % 96.1 % 
Kolliphor® EL 4.2 % 15.0 % 
 
Compound 31 in Kolliphor® EL showed the greatest anti-proliferative activity (table 
3.18) with a growth inhibition of 85 %. However, the control group showed a 95.8 % 
growth inhibition in A549 cells with. Kolliphor® EL was not pursued as a viable 
delivery method due to the high anti-proliferative effect of the control. 
The control groups of the remaining vehicles tested had no appreciable effect on the 
growth of the cells. From previous results we know that N-{6-ferrocenyl-2-
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naphthoyl}-glycine-glycine ethyl ester 31, when dissolved in 100 % DMSO and 
tested at a concentration of 1 µM, has a growth inhibition level of 75.2 ± 1.9 %. With 
the exception of Kolliphor® EL, the vehicle that allowed for the greatest activity of 
31 was 1 % carboxymethyl cellulose with a growth inhibition level of 39.8 %. This 
is a 1.9 fold reduction in activity. 80 mM citrate buffer, 5 % Ccarboxymethyl 
cellulose and 50 % propylene glycol all showed lower level of activity < 20 %. 
These activity levels are too low and so other avenues must be explored as a viable 
delivery system for these ferrocenyl compounds in vivo. 
 
3.4.2 PEGylation 
PEGylation is the covalent attachment of polythelene glycol (PEG) to another 
molecule, often a drug. Some of the desirable properties that make PEGylation an 
attractive option are the ability to avoid detection by the immune system, increasing 
hydrodynamic size to lengthen circulatory time and increasing solubility of 
hydrophobic drugs and proteins. 
PEGylation improves the pharmacokinetic and pharmacodynamic properties of 
polypeptide drugs by increasing water solubility, reducing renal clearance and 
limiting toxicity [250,251] 
A PEGylated derivative of for N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl 
ester (31) was synthesized (by Andy Garry Harry, School of Chemical Sciences, 
DCU) and was water soluble to at least 10 mM. However, the structural alteration 
had an effect on the cytotoxic activity of the compound as an IC50 value was not 
achieved using concentration up to 20 µM in A549 cells. 
 
3.4.3  Conclusion 
 
Our attempts to find a viable method for a delivery method in vivo of N-{6-
ferrocenyl-2-naphthoyl}-glycine-glycine ethyl ester (31) were ultimately 
unsuccessful. Additional avenues must be explored if the compound is to progress 
into animal studies and give a better assessment for the potential of these ferrocenyl 
derivatives as an anti-cancer agent. As discussed (section 1.5), lipid nanocapsules 
have recently already been shown as an effective delivery system for ferrocenyl 
compounds and as such would be worth exploring [225]. 
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4.1 Structure-Activity Relationship (SAR) studies 
 
4.1.1 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide 
esters 
 
The primary objective of this research was to explore a structure-activity relationship 
(SAR) study of the incorporation of alkyl chains moieties on the unsubstituted ring 
of the N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters. In previous 
studies carried out to evaluate the in vitro anticancer activity of N-para, N-meta and 
N-ortho-(ferrocenyl) benzoyl dipeptide esters, the general trend in cytotoxicity was 
para < ortho < meta [126-130]. The most active derivatives of the 1-alkyl-1’-N-
para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters are 1-methyl-1’-N-
{para-(ferrocenyl) benzoyl} glycine glycine ethyl ester 64, 1-ethyl-1’–N-{para-
(ferrocenyl) benzoyl} glycine glycine ethyl ester 76 with and 1-methyl 1’-N-{meta-
(ferrocenyl) benzoyl} glycine glycine ethyl ester 68. These compounds display 
improved bioactivity in comparison to the corresponding most active benzoyl 
analogues. 
1-alkyl-1’-N-ortho- derivatives exhibited lower percentage growth inhibition values 
compared to the meta and para derivatives for the dipeptides employed in the SAR 
study. Gly Gly (OEt) and Gly L-Ala (OEt) derivatives are more active than the Gly 
L-Leu and Gly L-Phe ethyl esters. It can be concluded that when chiral α-amino 
acids with bulky side chains are used as the second amino acid in the dipeptide 
moiety a loss of anti-proliferative activity is observed for this particular group of 
compounds. Cytotoxicity of the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) 
benzoyl dipeptide esters, decreases with the increase of the size of the alkyl group 
incorporated (propyl < ethyl < methyl) on the ferrocene moiety. The order of the 
amino acids in the dipeptide chain is crucial for activity, the trend being Gly Gly > 
Gly L-Ala > Gly L-Leu > Gly L-Phe. 
Incorporation of electron donating groups is a well know strategy to lower oxidation 
potentials of ferrocene moieties [131]. Thus, the incorporation of the various alkyl 
chain groups (electron donating groups) to the un-substituted cyclopentadiene ring of 
the N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters should 
improve the cytotoxicity of these derivatives. [126-130]. Incorporation of methyl and 
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ethyl alkyl groups results in an improved cytotoxicity of the para derivatives of the 
glycine glycine ethyl esters and an improved cytotoxicity of the methyl meta glycine 
glycine derivative. However, when the size of the chain length increased to ethyl the 
IC50 value was ca. three times higher than the unsubstituted analogue [129]. Thus, 
the increase in alkyl chain length resulted in a drastic decrease in the cytotoxicity of 
the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters. 
 
4.1.2 N-{para-(ferrocenyl)ethynyl benzoyl}, N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} and N-{5-(ferrocenyl)ethynyl-2-furanoyl} amino acid and dipeptide 
esters 
 
This SAR study involves the cytotoxicological evaluation of the incorporation of an 
ethynyl moiety between the ferrocene moiety and the conjugate linker. The 
incorporation of the -C≡C- moiety between the ferrocene moiety and the aromatic 
spacer and the use of three different aromatic rings are attempts to further improve 
the cytotoxicity of the previously prepared N-para, N-meta and N-ortho-
(ferrocenyl)benzoyl dipeptide esters. The ferrocene moiety is required for the 
possible production of hydroxyl radicals, the -C≡C- and conjugated aromatic linkers 
facilitates this process by lowering the redox potential of the ferrocene and the 
peptide fragment can interact with other molecules via hydrogen bonding. 
The incorporation of a methyl derivative to the unsubstituted cyclopentadiene ring of 
the N-(ferrocenyl) benzoyl dipeptide derivatives showed an enhancement of the anti-
proliferative effect, atlthough methyl ester derivatives exhibited lower percentage 
growth inhibition values compared to the ethyl ester derivatives.  
Gly L-Leu and Gly L-Phe ethyl esters displayed low growth inhibition activity. 
Thus, the Gly L-Leu and Gly L-Phe ethyl ester derivatives were not investigated 
further. As a result, it can be concluded that when chiral α-amino acids with bulky 
side chains are used as the second amino acid in the dipeptide moiety, a loss of anti-
proliferative activity is observed for this particular group of compounds. 
The presence of the ethynyl moiety had a negative effect of anti-proliferative effect 
compared to analogous compounds prepared previously lacking the ethynyl group 
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and the the furanoyl ring is not a bioactive aromatic conjugate linker that promotes 
anti-proliferative effect. 
We have previously postulated the potential of these ferrocenyl dipeptide derivative 
compounds to interact with DNA and that this interaction could play a role in the 
anti proliferative effects of the compounds [132]. It has been seen in polyaromatic 
drugs, such as anthracyclines, that they can inhibit DNA and RNA synthesis by 
intercalating between base pairs and prevent cancer cells from replicating. If these 
polyaromatic ferrocenyl derivatives also have the ability to interact with DNA/RNA 
then the hydrogen bond donor and acceptor atoms present in the peptide side chain, 
could then interact with the nucleotide bases positioned in the centre of the helix. 
The presence of the ethynyl group may disrupt this interaction. There is also a 
possiblility that ferrocene, in its oxidized Fe
3+ 
state could interact with the negatively 
charged phosphate backbone of the DNA double helix. Thus, it is possible for the 
naphthoyl ferrocenyl bioconjugates to possess two distinct modes of action: the 
ability to cause oxidative damage to DNA through ROS production and the ability to 
intercalate with DNA, both of which would result in the disruption of cancer cell 
replication. [132] 
 
4.1.3. Conclusion 
 
From the results of the SAR studies of the two groups; 1-alkyl-1’-N-para, N-meta, 
N-ortho-(ferrocenyl) benzoyl dipeptide esters and N-{para-(ferrocenyl)ethynyl 
benzoyl}, N-{6-(ferrocenyl) ethynyl-2-naphthoyl} N-{5-(ferrocenyl)ethynyl-2-
furanoyl} amino acid and dipeptide esters, there was a large range of IC50 which 
ranged from the most active, 2.6 ± 0.6 µM (68) to the compound with the highest IC 
50 value, 23 ± 5.1 µM (129)  to many that were not active enough to pass the 10 µM 
screen. IC50 values of      < 5 µM are among the lowest this group has produced, 
however we have synthesized and biologically evauluated compounds in the 
nanomolar range. The trends we have seen in these compounds can be investigated 
to improve biological activity of some of the most active compounds in the continual 
effort to produce an improved anti-cancer compound. 
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4.2. N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine- compounds with altered 
ester moiety 
 
N-(6-ferrocenyl-2-naphthoyl) glycine glycine ethyl ester 31 has previously been 
evaluated by this group and was the most active compound tested, with an IC50 of 
0.13 ± 0.02 and 1.10 ± 0.13 in H1299 and Sk-Mel-28 respectively. 
For this reason it was selected to perform a SAR to evaluate the role of the ester 
moiety on biological activity. N-(6-ferrocenyl-2-naphthoyl) glycine glycine ethyl 
ester was used as a reference as well as derivatives that replaced the ethyl ester with 
a methyl, propyl, butyl and benzyl ester. An initial screening at 10 µM showed there 
to be no correlation between ester moiety and activity. There was a trend that 
showed a slightly lower activity level of each compound in HT-144 and A549 cells 
when compared to Lox-IMVI, MalMe-3M and H-1299 cells. The compounds were 
then tested at 1 µM, at which point the biological activity of propyl, butyl and benzyl 
derivatives had all dropped to < 10 % growth inhibition. At 1 µM, the methyl 
derivative 30 showed an improvement in activity to the reference compound 31.  It 
appears that the ester moiety plays a crucial role in the biological activity of these 
compounds and a shorter chain is favoured. This is confirmed when the IC50 values 
are taken into account. Across all cell lines N-(6-ferrocenyl-2-naphthoyl) glycine 
glycine methyl ester 30 has a lower IC50 when compared to N-(6-ferrocenyl-2-
naphthoyl) glycine glycine ethyl ester 31. It is also worth noting that both 
compounds have a lower IC50 than cisplatin. As cisplatin is commonly used as a 
single agent, and as part of a chemotherapy regimen, this is a promising early result 
for the potential of these ferrocenyl compounds. 
The IC50 value for N-(6-ferrocenyl-2-naphthoyl) glycine glycine ethyl ester 31 was 
found to be markedly higher in H1299 cells than in any of the other cell lines tested. 
Also, from previous results the IC50 of 31 was found to be 0.13 ± 0.02 µM in H1299 
cells, however when tested as a reference compound concurrently with 30 it was 
found to be 1.4 ± 0.21 µM,  a > 10 fold decrease in activity. Potential reasons for this 
are discussed in section 4.3 
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4.3 Further cytotoxicological evaluation of N-(6-ferrocenyl-2-naphthoyl) 
glycine glycine methyl ester (30) and N-(6-ferrocenyl-2-naphthoyl) glycine 
glycine ethyl ester (31) 
 
Given the strong anti-proliferative effects of N-(6-ferrocenyl-2-naphthoyl) glycine 
glycine methyl ester (30) and N-(6-ferrocenyl-2-naphthoyl) glycine glycine ethyl 
ester (31), additional cytotoxicological evaluation was warranted.  
Resistance to chemotherapeutics is a major concern when trying to treat any cancer 
type. Cancer cells exhibit resistantance to chemotherapeutics for a number of 
reasons. Broadly, some of these reason are i) intrinsic resistance, where a cancer cell 
is naturally resistant to a certain chemotherapy treatment, ii) acquired resistance, 
where a cancer cell develops resistance to a chemotherapy treatment that was once 
effective and iii) multiple drug resistance, where a cancer cell may have developed a 
mechanism of resistance that can affect the activity of more than one chemotherapy 
treatment. An example of multiple drug resistance can be seen between cisplatin and 
temozolomide, both of which share a common resistance to mismatch repair. HCT 
116 (MLH1 mutant) and DLD1 (MSH6 mutant) MMR deficient colon carcinoma 
cells are resistant to TMZ treatment. MMR-deficient cells are reported to be up to 
100-fold less sensitive to methylating agents compared with their MMR proficient 
counterparts. MLH1 deficiency is also associated with cisplatin resistance [255-260]. 
Low MSH2 (which forms a heterodimer with MSH6) levels predict cisplatin benefits 
in patients with resected lung cancer and high MSH2 levels are a positive prognostic 
factor for untreated lung cancer patients [253,257,258,260]. 
We tested N-(6-ferrocenyl-2-naphthoyl) glycine glycine methyl ester 30 and N-(6-
ferrocenyl-2-naphthoyl) glycine glycine ethyl ester 31 in two cell line models of 
acquired resistance to cisplatin and temozolomide, to determine if either of these 
compounds could overcome the cisplatin/temozolomide resistance mechanisms. The 
specific resistance mechanisms to cisplatin and temozolomide in these cells have not 
yet been elucidated. 
From the IC50 values, Compound 31 shows no significant variation in activity 
between the parental and resistant cell lines whereas the cells show resistance to 
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compound 30 which indicates that 30 is susceptible to similar mechanisms of 
resistance to that of cisplatin and temozolomide.  
Cell cycle analysis in both A549 and HT-144 cell lines has shown N-(6-ferrocenyl-2-
naphthoyl)-glycine-glycine methyl ester 30 causes a significant increase in the sub-
G0/G1 peak, which is suggestive of apoptosis and/or necrosis.  
Due to apoptosis being heavily implicated as a primary mode of action of N-(6-
ferrocenyl-2-naphthoyl) glycine glycine methyl ester 30 and N-(6-ferrocenyl-2-
naphthoyl) glycine glycine ethyl ester 31, TUNEL analysis was undertaken in A549 
and HT-144 cells with N-(6-ferrocenyl-2-naphthoyl) glycine glycine methyl ester 30. 
A dose dependent relationship was observed between the concentration of 30 and the 
induction of apoptosis. This further implicates apoptotic induction as a primary 
mode of action of N-(6-ferrocenyl-2-naphthoyl) glycine glycine methyl ester 30. 
When we compare the results of the cell cycle and TUNEL assay we can see that 
levels of apoptosis appear higher in the TUNEL analysis when compared to the sub 
G0 fraction, indicative of apoptotic/necrotic cells, of the cell cycle analysis. A reason 
for this may be that in order for cells to be seen in the Sub G0/G1 area, they must 
have lost enough DNA to appear there; so if cells enter apoptosis from the S or G2/M 
phase of the cell cycle or if there is an aneuploid population undergoing apoptosis, 
they may not appear in the Sub G0/G1 peak [82]. Also cells that have lost DNA for 
any other reason, for example, death by some other form of oncosis, will appear in 
the SubG0/G1 region; so we have to be careful about how we define the sub G0/G1 
peak [84]. As with all methods that are used to detect apoptosis, the more processing 
steps involved, the greater the likelihood of losing cells and apoptotic and necrotic 
cells are sometimes preferentially lost [84]. Although late-stage apoptosis has been 
implicated as a mode of action of 30, like many other chemotherpaeutics, this may 
not be the only method whichis in effect. We know that ROS production has an 
effect on many cellular processes and as such, other modes of action are worthy of 
further investigation.  
Another major problem with chemotherapeutic regimens is the side effects that 
generally accompany them. As chemotherapy treatment is generally systemic, side 
effects arise from cytotoxic agents affecting healthy cells as well as cancer cells. As 
such, we attempted to address this issue by testing N-(6-ferrocenyl-2-naphthoyl) 
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glycine glycine methyl ester 30 and N-(6-ferrocenyl-2-naphthoyl) glycine glycine 
ethyl ester 31 in NHDF cells, using cisplatin as a reference. The IC50 results showed 
that 30 and 31 are less cytotoxic than cisplatin in NHDF cells. As ROS production is 
thought to play an important role in the anti proliferative effect of ferrocenyl 
compound, the reason why the compounds tested have such high activity levels in 
cancer cells but not NHDF cells may be due to the increased regulation of ROS in 
healthy cells compared to cancer cells. The difference in activity between cancer 
cells and normal cells would suggest that healthy cells tolerate the compounds better 
than cancer cells. Selectivity of chemotherapeutics to cancer cellsis a highly 
desirable quality as it may suggest reduced side effects to the drug.  
 
4.4 Future work 
 
Previous studies of N-(6-ferrocenyl-2-naphthoyl) glycine glycine ethyl ester 31 have 
shown an IC50 0.13 ± 0.02 µM in H1299 cells, whereas in the SAR study reported 
here, the IC50 value achieved was increased by greater than 10 fold (1.4 ± 0.21 µM). 
Although precautions were taken to ensure reproducibility in results there are a 
number of factors which may account for the difference in activity. The compound 
used was of the same batch, however the compound was stored for many months 
before further testing. The compound is thought to be stable and was evaluated by 
TLC and NMR before testing and showed no degradation, when variations in IC50 
values were first notices, TLC analysis was carried out again and showed no 
degradation. Before testing, 31 was weighed using an analytical balance, however 
some discrepancies in making stock solutions may contribute to the difference in 
activity. The H1299 cells were obtained from an internal cell repository and may 
contribute to a potential difference in activity levels. Differences in FCS (Foetal Calf 
Serum) batches, which is added to the growth medium, play a role in the 
characteristics of the cells and can effect responsiveness to drugs.  Some or all of 
these factors may play a role in the discrepancies in activity from those previously 
reported. This issue should be addressed before further analysis is undertaken. 
The natural progression of compounds which have shown strong anti-cancer 
properties is an evaluation in vivo. DMSO is one of the most common solvents used 
experimentally to dissolve hydrophobic substances for in vitro testing. All of the 
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compounds tested were dissolved in DMSO and an equivalent volume was used to 
ensure that DMSO alone had no anti-proliferative activity. Although DMSO can be 
used as a delivery method of compounds in vitro, it is not well tolerated for in vivo 
models. Due to this reason we explored a number of alternative delivery methods 
and used N-{6-ferrocenyl-2-naphthoyl}-glycine-glycine ethyl ester 31 to test the 
efficacy of the drug delivery vehicles. Suspension of 31 in Kolliphor EL was the 
only drug delivery method which demonstrated a similar anti-proliferative effect in 
vitro when compared to DMSO delivery; however the control group showed an even 
greater affect. For this reason it cannot be concluded that the biological activity is 
due to 31. 80 mM citrate buffer, 5 % carboxymethyl cellulose, 1 % carboxymethyl 
cellulose and 50 % propylene glycol solution all significantly reduced the activity of 
31. Alternative methods of drug delivery are necessary before these ferrocenyl 
compounds can be tested in an in vivo model.  
PEGylation and Intralipid have both been used as a method of drug delivery for 
hydrophobic compounds [253,254]. Attempts to use PEGylation as an effective 
method of drug delivery for ferrocenyl compound 31 was unsuccessful as it removed 
all anti-proliferative activity of the compound, which further strengthens the 
hypothesis that the structural composition of the compound plays a pivotal role in its 
activity. 31 was also completely insoluble in intralipid. 
Nanocapsules show great potential in overcoming the water solubility issue of these 
molecules as they offer benefits such as increased bioavailability, protection against 
in vivo degradation and enhancement of pharmacokinetic properties as well as 
greatly increasing solubility in water [255].  LNCs (lipid nanocapsules) are a 
promising alternative as they have already been tested successfully in vivo with the 
ferrocenyl compound, FcOHTAM. FcOHTAM was encapsulated in an LNC and 
tested in vivo in xenografted triple negative breast cancer mice. As a consequence, a 
significantly lower tumor volume was obtained at the end of the experiment with a 
difference of 36 % at day 38 compared to the untreated group. The LNC was also 
shown to have no effect on the IC50 value [132]. For these reasons, LNC’s make a 
great candidate for the advancement of compounds 30 and 31 into in vivo testing 
[256]. 
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As ROS is implicated as being a factor in the mode of action of ferrocenyl 
compounds (section 1.3.1.2.1). This is possible via a Fenton-type reaction, in which 
HO
•
 radicals are generated from the superoxide dismutation product, hydrogen 
peroxide (H2O2). To investigate this, the rate of Fenton-reaction mediated 8-oxo-7,8-
dihydroguanine (8-oxoGua) [257] formation from guanine was monitored. Guanine 
was chosen as it has the lowest oxidation potential of all the DNA bases and is 
considered the clinical biomarker for oxidatively damaged DNA [258] We have 
previously reported on the ability of these  derivatives to utilize this as a mode of 
action and studies confirm that 31 is capable of causing oxidative damage to 
guanine, and it does so by the generation of HO
•
 radicals from H2O2 The hydroxyl 
radical (HO•) generated oxidises guanine to oxo-8-guanine thus altering the base 
pairing sequence to adenine which results in DNA damage leading to cell apoptosis 
[259].  
It would be of interest to investigate the levels of ROS produced by some of the most 
active ferrocenyl compounds. The production of quinone methide has also been 
shown to play a role in the activity of ferrocenyl compounds. The oxidation of 
ferrocene promotes the oxidation of one phenol group into a quinone methide 
through a proton transfer coupled to an intramolecular electron-transfer mechanism 
[123]. This is expected to damage target cells by forming adducts with biological 
bases, such as DNA or proteins [124–125].  As DNA damage is also thought to play 
a role in the activity of the compounds tested, identification of quinine methide 
production would be worth exploring. 
Further investigation into the specific mode(s) of action involved in the anti-
proliferative activity of these compounds would be valuable. Protemomic profiling 
would be of interest, particularly in relation to the method N-(6-ferrocenyl-2-
naphthoyl) glycine glycine methyl ester 31 uses to overcome cisplatin and 
temozolomide resistance which could be compared against N-(6-ferrocenyl-2-
naphthoyl) glycine glycine ethyl ester 30 which was sensitive to the resistant cells. 
As seen in section 1.4, ferrocenyl compounds have shown to have an effect on 
apoptosis relevant protein harikiri [260]. As apoptosis is shown to play an important 
role in the activity of 30 and 31, proteomic analysis could shed new light on the 
cellular interactions of these ferrocenyl compounds. 
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4.5. Summary and Conclusion 
 
In summation, we have investigated a number of structure-activity relationships that 
have shown us the importance of the structural composition to the biological activity 
of these ferrocenyl compounds. We have also identified our most active compound 
to date, N-(6-ferrocenyl-2-naphthoyl) glycine glycine methyl ester 30 with IC50 
values in a nanomolar range. This compound has a number of characteristics that 
make it a viable option for further investigation, such as: 
 
(i) Strong anti-proliferative activity in cancer cells with nanomolar 
concentrations, greater than that of cisplatin. 
(ii) Low cytotoxity in NHDF cells, of a similar level as cisplatin. 
(iii) Selectivity of activity to cancer cells. 
(iv) The ability to overcome multiple drug resistance (MDR). 
 
Further investigation into the mode of action of these compounds would be of 
interest, particularly protemomic work to identify target proteins involved in 
multiple drug resistance, quinine methide production as well as internal ROS 
production. LNC’s may hold the key to overcoming the solubility issues associated 
with these ferrocenyl comounds and if this is the case then in vivo is an important 
next step to evaluating the most active compound, N-(6-ferrocenyl-2-naphthoyl) 
glycine glycine methyl ester 30. 
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Abbreviations 
 
IC50  - Inhibitory concentration 50 % 
TUNEL - Terminal DNA transferase-mediated dUTP nick end labelling 
UV  - Ultra Violet 
HPV  - Human papillomavirus 
HRT  - Hormone Replacement Therapy  
NSCLC - Non-Small-Cell Lung Cancer 
SCLC  - Small-Cell Lung Cancer 
SEER  - Surveillance, Epidemiology, and End Results 
DTIC  - Dacarbazine 
CVD  - cisplatin, vinblastine and dacarbazine 
CTLA-4 - Cytotoxic T-lymphocyte associated antigen 4 receptors 
gp100  - glycoprotein 100 
BRAF  - V-raf murine sarcoma viral oncogene homolog B1 
FDA  - Food and Drug Administration 
IUPCA - Internation Union of Pure and Applied Chemistry 
DNA  - Deoxyribonucleic Acid 
RNA  - Ribonucleic Acid 
cis-DDP - cis-diamminedichloroplatinum 
ROS  - Reactive Oxygen Species 
SOD  - Superoxide Dismutase 
GSH  - Glutathione 
ER  - Estrogen Receptor 
KP46  - tris(8-quinolinolato)gallium(III) 
KP1019 - indazoliumtrans-[tetrachlorobis(1H-indazole)-ruthenate(III)] 
NAMI-A - imidazolium trans-[tetrachloro-(S-dimethyl sulfoxide)(1H-
imidazole)ruthenate(III)] 
NO  - Nitrous Oxide 
RAPTA - Ruthenium Arene 1,3,5-Triaza-7-Phosphaadamantane 
MDR  - Multiple Drug Resistance 
Pgp  - Permeability Glycoprotein 
Vcr  - Vincristine 
Bcl-2  - B-cell lymphoma 2 
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Bax  - Bcl-2-associated X protein 
Bak  - Bcl-2 homologous antagonist killer 
ATP  - Adenosine triphosphate 
NADH  - Nicotinamide adenine dinucleotide 
TrxR  - Thioredoxin reductase 
LD50  - Median Lethal Dose 
DMSO  - Dimethyl sulfoxide 
PEG  - Polyethylene glycol 
LNC  - Lipid Nanocapsule 
TNBC  - Triple-Negative Breast Cancer 
FCS  - Fetal Calf Serum 
DMEM - Dulbecco's modiﬁed Eagle's medium 
RPMI  - Roswell Park Memorial Institute medium 
Cpt  - Cisplatin 
ATCC  - American Type Culture Collection 
NICB  - National Institute of Cellular Biotechnology 
PBS  - Phosphate Buffered Saline 
Fc-OH-TAM - Hydroxy-Ferrocifen 
PI  - Propidium Iodide 
SAR  - Structure-Activity Relathionship 
OEt  - Ethyl ester 
OMe  - Methyl ester 
OBu  - Butyl ester 
OBn  - Benzyl ester 
OPr  - Propyl ester 
GABA  - gamma-Aminobutyric acid 
TMZ  - Temozolomide 
OH•  - Hydroxide Ion       
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